ESMO 2026 Conference Intelligence

FOLFIRI plus ramucirumab vs paclitaxel plus ramucirumab as 2L therapy for taxane-pretreated patients with mGEA–Final results of the phase III IKFs602/AIO RAMIRIS Study #ESMO26 #ESMOAmbassadors 👉 ORR: 25 vs 23% 👉 mPFS: 5.5 vs 3.7 mo 👉 mOS: 8.7 vs 7.5 mo 🧐neg. study, but FOLFIRI + Ram appears reasonable option @myESMO @ASCO

HERIZON-GEA-01 at #ESMO26: Zanidatamab + chemotherapy improved PFS and OS versus trastuzumab-based therapy in 1L HER2+ advanced GEA. The triplet regimen with tislelizumab achieved a median OS of 27 months and a 3-year OS rate of 40%. @OncoAlert #HER2Positive https://t.co/U7iPdH0TRg

thanks for your reply. Actually, neoadjuvant pembro is not necessarily the standard for resectable Stage III; based on the NADINA study and on clinical judgement, ipi/nivo combo neoadjuvant therapy is often used instead of single agent pembro. It is paradoxical but true; the more approved or "proven" (but not FDA approved) therapies there are, the harder it is to design the next study. What is the "standard" treatment you compare to? Will all experts/investigators be able to agreed to such a standard? Will the comparison remain meaningful through trial data completion? There are also other historical comparison trials of single agent adjuvant immunotherapy for #melanoma, whose patient cohorts and endpoints may be more comparable. Again, it all comes down to full data disclosure tomorrow (and the inevitable simultaneous @NEJM or other publication).

🔬 Left ureter transposition during robotic cystectomy. How do you safely navigate between the sigmoid mesentery, hypogastric plexus, and iliac vessels? 🎥 Watch more surgical tutorials on YouTube 👇 https://t.co/Qj7xYgYIUt While #ESMO26 focuses on optimizing perioperative systemic therapy, let's not forget to optimize surgical technique too! @ERUSrobotics

From the full poster, today at ESMO (BeOne Medicines). https://t.co/dLgR00kQys

Shrinkage of brain metastasis in a patient with MTAP-deficient lung cancer treated with BeOne's PRMT5 inhibitor. A reason for optimism that this class may have activity in glioblastoma (~40% MTAP-deficient)?

Some tentative good news today for a vaccine in pancreas cancer. - 7-valent mutant KRAS vaccine (G12D, G12R, G12V, G12A, G12C, G12S and G13D) given after surgery and completion of chemotherapy (with or without radiotherapy) in patients with stage I-III KRAS-mutant pancreas cancer. - This did not prevent recurrence in the overall population. - But, when split into pre-specified groups: ctDNA+ vs. ctDNA-, or presence/absence of prior radiation, there was significant (and substantial) protection. - It's unclear how this KRAS vaccine will interact with KRAS inhibitors in the future. The vaccine is made by Elicio Therapeutics, the data were presented by Eileen O'Reilly at ESMO - it's now moving to phase 3.

🩸🇪🇸 ESMO 2026 MYELOMA + MADRID GUIDE Myeloma in the morning. Tapas at night. 😆 📍 Madrid | Oct 23–27 ⭐ Essential session: Sat Oct 24, 08:30–10:00 Salamanca Auditorium, Hall 10 Three myeloma oral presentations: 1️⃣ 1454O—Bela-DRd in transplant-ineligible NDMM High MRD negativity sounds excellent—but what does belamaf truly add beyond DRd? We need durable PFS, tolerability and ocular-treatment burden—not another impressive MRD snapshot. 2️⃣ 1455O—Long-term BelaRd The important question is durability. Is frontline BCMA exposure justified when CAR-T and bispecific antibodies may be needed later? 3️⃣ 1456O—LBL-034, a new GPRC5D×CD3 bispecific in heavily pretreated RRMM Phase I and single-arm: promising, not practice-changing. Watch duration of response, infections, EMD activity and the familiar GPRC5D taste/skin/nail toxicities. BOTTOM LINE: ESMO myeloma is small but focused: ➡️ Belamaf moving earlier ➡️ Another GPRC5D bispecific moving forward ➡️ No phase III result likely to change practice immediately 🍖 NOW THE IMPORTANT SESSION: IBÉRICO! Easiest post-ESMO stop: 🥇 Cinco Jotas Padre Damián—excellent 100% ibérico de bellota and convenient after taking Metro Line 8 from IFEMA toward Nuevos Ministerios. For the complete Madrid experience: 🥓 Joselito’s Velázquez—destination-quality jamón 🍤 La Casa del Abuelo—gambas al ajillo 🍳 Casa Lucio/Huevos de Lucio—huevos rotos 🍺 Bodega de La Ardosa—tortilla, vermouth and old-Madrid atmosphere Scientific rule: Do not confuse MRD negativity with cure. Madrid rule: Do not confuse ordinary ham with jamón ibérico de bellota. 😆 #ESMO2026 #MultipleMyeloma

These Kaplan-Meier curves finally separate… by about the width of a pixel... The curves ride on top of each other for years before a modest late subatomic divergence, and then the blue arm takes a dramatic vertical plunge at the far righ, right about the time the numbers at risk collapse to single digits. Truly a triumph of statistical significance over clinical drama. Novartis is already calling a ~20% relative reduction “clinically meaningful.” Somewhere a health economist is quietly calculating the cost per life-year for treating 5,100 patients to avert ~27 deaths.@5_utr

The future of ADCs: not only bispecific, but also dual-payload? Phrontline Biopharma is leading the charge here, with at least three programs moving to first-in-human studies. I spoke to them today at ESMO - impressive scientists and impressive science! https://t.co/Bev69zx7vG https://t.co/hwdE0PkCiT

At dinner with the best medical affairs team anywhere, celebrating a fantastic day 1 of #ESMO26! A little fun after an exhilarating day of science never hurt anyone… https://t.co/AeBIvKBFwS

Proud of our superstar fellow @elioibrahim8 presenting his work on clinical & transcriptomic correlates of primary resistance to nivo/ipi in metastatic RCC at #ESMO26! Important work toward understanding why some patients do not respond to immunotherapy! @myESMO @oncoalert https://t.co/rGNPMdFNJL

Day 1 #ESMO26 highlights by @OncBrothers 👇 https://t.co/yxmof0qXBu

No better way to start a visit to the Madrid that with lunch with my onc sisters @AnaVManana and @ShrutiPatelMD #ESMO26 https://t.co/jBnlmvw3XR

Day 1 #ESMO26 highlights Breast Ca 1. #NATALEE (update): Ribo Adj HR+ 2. #HorizonBreast06: ADCs in mBC 3. #TALENT: NeoAdj TDXd HR+ GI 4. #RASolute302: Panc Ca 5. #HerizonGEA01: GEJ/Gastric GU 6. #KN866: NeoAdj Pembro MIBC 7. #PEACE1: Abi in mHSPC #OncTwitter @myESMO 1/8 https://t.co/pkQxyvyRrG

ABBV-969 dual-targeting ADC #ESMO26 MOA = PSMA/STEAP1— TOPO1 Deep responses in metastatic castration-resistant prostate cancer Surely this one can beat Docetaxel? https://t.co/NRR8xw9KS3

Arriving at #ESMO26 tomorrow just in time for what promises to be one of the most exciting sessions: Presidential Session #1. #INTerpath-001 presented by @ProfGLongMIA, #VOLGA by @tompowles1, #DeLLphi-305 by @sands_jacob & #DASLHiCaP by @niazi_Dr7. A terrific slate of discussants as well, incl @StephenVLiu (one of the most talented orators in our field, IMHO), @MichvdHeijden, @Silke_Gillessen & more. Hats off to @YJanjigianMD, @FAndreMD, @Prof_Nadia_H & #DrJamesLarkin for assembling a powerhouse program! @OncoAlert

MASTERPLAN full publication is out!! The RT volumes are worth a closer look. CTV = primary GTV + nodal GTV + tumour-vessel interface. The TVI extends 5 mm proximally and 5 mm distally along involved/closely adjacent vessels, for patients where surgery is likely. PTV = CTV/ITV + 5 mm. No elective nodal irradiation, and no elective perineural or celiac/SMA plexus volume specified in the protocol. That is a focused target, with gross nodal disease included. Real-time RTQA is a big part of this story. Review identified 36 major planning deviations in 12 patients, reduced to 2 deviations in 2 patients after QA. All plans passed independent review before treatment. As a radiation oncologist, I want that detail alongside the outcomes. Reproducing the treatment means reproducing the contour review, OAR constraints and image guidance too. Also worth keeping the treatment delivery denominator in view: only 40/49 patients assigned to SBRT actually received it (82%). The efficacy analysis is intention-to-treat. It should not be read as an outcome series of patients who all completed SBRT. The surgical numbers need some unpacking. All comparisons below are chemo + SBRT vs chemo alone: ✅ Underwent surgery: 62% vs 44% (29/47 vs 11/25). ✅ Completed resection: 53% vs 44% (25/47 vs 11/25). ✅ R0 among all resected patients: 52% vs 36% (13/25 vs 4/11). ✅ R0 in the resected POPC subset: 62% vs 40% (13/21 vs 4/10). POPC is the potentially operable cohort. So the 62% surgery figure includes exploration without resection, while the 62% R0 figure applies only to resected POPC patients. These are different endpoints with different denominators. None of those between-arm surgical comparisons was statistically significant. The paper also defines R0 as more than 1 mm clearance. Adjuvant chemo is another important difference: 80% vs 36% of resected patients received it (20/25 vs 4/11). That complicates attribution within the treatment pathway. Early progression in the control group may have contributed, so this is a post-randomisation imbalance with more than one possible explanation. The post-hoc analyses were directionally consistent, but the authors explicitly caution about selection bias. For the planning details: PTV_EVAL excluded the GI PRVs, with a minimum 3 mm PRV expansion. OAR constraints took priority over target coverage. Duodenum, stomach and small bowel D0.5cc were each constrained to <33 Gy, with V30 <5 cc. Delivery used standard linacs; breath hold was recommended, and fiducials were placed in 35/40 patients (88%). This is relevant to how we would implement the approach in practice. With no elective nodes, isolated regional nodal relapse was 4% vs 8% (2/49 vs 2/25). Reassuring, although that does not establish the optimal elective volume (especially considering these patients went to surgery - ASTRO/NRG recommends inclusion of elective perineural coverage). Overall G3+ AEs were 70% vs 64% (33/47 vs 16/25). One G3 pancreatitis and one G2 small bowel obstruction were attributed to SBRT. The practical takeaway for me is to keep the target definition and prospective QA attached to the results, and to be precise about what the surgery and R0 numbers actually measure.

Delighted to join Dr Yi-Chen Zhang, Dr Calvo de Juan and Prof Yi-Long Wu in discussing the role of local therapy in non-small cell lung cancer at #ESMO26 in #Madrid this afternoon. Superb case discussion and fascinating insights into novel approaches such as the role of ctDNA In selection and monitoring of patients. @myESMO @CancerInstIRE @tcddublin @TrinityMed1

INCB123667 + bev in #PROC. Selective CDK2 inhibitor, n=23. ORR 48%, mPFS 7.4 mo, responses after PARPi and after prior bev. Single arm. Bev alone in PROC was about 16%. MAESTRA 3 will test CDK2i + bev vs bev. 87% cyclin E1 overexpressed, so IHC barely selects. We need response by CCNE1 amplification. Endometrial was in phase 1. All three pivotal trials are ovarian. 28% of p53abn endometrial cancers carry CCNE1 amplification, enriched in carcinosarcoma. That cohort deserves its own trial. #gyncsm #ESMO26

Sad that the @myESMO embargo was broken... It is difficult to compare results between an adjuvant study and a neoadjuvant study (ie, S1801) in any cancer, including #melanoma. The patient populations were different and the primary endpoint (RFS vs EFS) was of necessity different for technical reasons that as @adamfeuerstein points out don't translate well to this platform. Until tomorrow's presentation we won't have all the data necessary to even try and compare. It is also important to note that NO drugs are technically @FDA approved for neoadjuvant treatment for melanoma. It's a moot point as several studies including S1801 and NADINA have made neoadjuvant therapy standard of care in some situations. I think it's great that the study (that I participated in) appears to have hit its primary endpoint, which typically ultimately translates into FDA approval. Tomorrow (1030 ET) will be interesting...

Proud to share our work with @carisls studying the impact of G protein coupled estrogen receptor and estrogen receptor in EGFR mt NSCLC showing significant differences in outcomes with high expression of GPER and low expression of ESR1/2. #ESMO26 #lcsm @uscnorris https://t.co/um0atjiIIK

💉لقاح mRNA شخصي يقلل خطر عودة سرطان الجلد أو الوفاة بنسبة 42% 📉 أعلنت شركتا Moderna⁠ و Merck⁠ نتائج تجربة INTerpath-001 من المرحلة الثالثة 📉 اختبرت التجربة لقاح Intismeran autogene المصمم خصيصاً وفق الطفرات الجينية لورم كل مريض بشكل شخصي بالإضافة إلى العلاج المناعي Pembrolizumab بعد الاستئصال الجراحي لسرطان الجلد الميلانيني عالي الخطورة 📉 شملت التجربة أكثر من 1,100 مريض 📉 النتيجة 🔹انخفاض الخطر النسبي Relative Hazard Reduction لعودة السرطان أو الوفاة 42% 🔹انخفاض الخطر النسبي للانتشار البعيد أو الوفاة 38% 🔹البقاء دون عودة السرطان مع العلاج المركب 82.2% و تمثل نسبة المرضى الذين بقوا دون عودة السرطان أو الوفاة خلال عامين Recurrence-Free Survival 🔹البقاء دون عودة السرطان مع Pembrolizumab وحده 70% 📉 الأهمية السريرية: يمثل هذا أول دليل من المرحلة الثالثة على فائدة سريرية للقاح سرطاني شخصي قائم على تقنية mRNA عند إضافته إلى العلاج المناعي ❗️النتائج مشجعة انخفاض الخطر النسبي بنسبة 42% لا يعني انخفاض الوفيات وحدها بهذه النسبة بيانات البقاء الكلي غير مكتملة و لم يحصل اللقاح بعد على الموافقات التنظيمية https://t.co/Znw4S3Pl7Z https://t.co/wGMx1VeKui https://t.co/FXD240UPQd

Impressive MRD analysis presented by @YukinoriOzaki. Pts with high-risk breast cancer who, at any point, turned MRD+, had clearly higher risk of recurrence compared to those constantly remaining MRD-. Clinical utility needs to be established prior to broad implementation. #ESMO26 https://t.co/q624zwJyqP

🚨 My top 4 #Melanoma #ESMO26 GC101 TIL: TILs without the full toxicity baggage? Randomized phase II in >=2L anti-PD-1-resistant melanoma! Notably 73% acral/mucosal!!! ▪️PFS: 4.37 vs 1.61m (HR 0.44) 💥 ORR: 44% vs 8% -Acral: ORR 45% vs 8% -Mucosal: ORR 50% vs 0% IL-2-free + reduced-intensity lymphodepletion 👀 and the discussant questioned whether 50% dose sintilimab really changes much… @OncoAlert @OncoReporte @myESMO @_SEOM @GrupoMelanoma

🚨#ESMO26 IOV-COM-202: bringing TILs upfront! Lifileucel + pembrolizumab in ICI-naïve advanced melanoma. 💥 ORR 62.5% | CR 29.2% ▪️ mPFS 19.8m | mDOR NR | 13/15 responses ≥12m Now TILVANCE-301 has to advance the signal 👀 @OncoAlert @OncoReporte @myESMO @_SEOM @GrupoMelanoma https://t.co/tdb3PQfpij

🚨📣 big news at #ESMO26: 🧵1/MASTERPLAN RCT shows adding SABR to perioperative chemotherapy for high-risk localized #pancreatic cancer ⬆️⬆️ median overall survival to 22.0 months vs 14.0 months (HR 0.45). #PancreaticCancer #RadOnc @TROGfightcancer in press @TheLancetOncol - https://t.co/KhPO4dgZd4

My top 🥈💎 #Melanoma #ESMO26 STARBOARD - Triplet therapy in BRAF V600 melanoma: enco + bini + pembro vs pembro alone in 1L. 💥 ORR: 70% vs 32.7% || mPFS: 33.0 vs 3.4 mo ▪️G3/4 TEAEs: 70% vs 39% OS: positive trend, but immature after early trial closure. Impressive PFS! But STARBOARD has not reached the OS shore yet⚓ @OncoAlert @OncoReporte @myESMO @_SEOM @GrupoMelanoma

8/8 My takeaways: cyclin E1 overexpression by IHC is becoming the selection biomarker for CDK2 and WEE1 programs, reaching more patients than amplification.

7/8 Tolerability is the issue to solve: dose interruptions 57%, reductions 43%, discontinuations 20%, grade ≥3 fatigue 16% and thrombocytopenia 12%. Mitigation in Part 2a reportedly halved discontinuations to ~10%. https://t.co/SBSZhPia0X

6/8 OS benchmarks: ~13 mo with single-agent chemo (AURELIA), 16.9 mo with mirvetuximab in FRα-high disease (MIRASOL). High cyclin E1 usually carries worse prognosis, so a longer OS in cyclinE1+ tumors points toward a drug effect. But: cyclin E1 status was assigned retrospectively with a proprietary cutoff, the CIs overlap and there is no control arm. ASPENOVA (azenosertib vs chemo, n≈420) and DENALI Part 2 will tell us if this holds.

5/8 Cyclin E1 IHC+ (n=48): ORR 33.3% (37.2% in response-evaluable) mDOR 5.5 mo mPFS 4.1 mo (confounded by early withdrawal) mOS 15.9 mo (95% CI 8.7–21.2) Cyclin E1 IHC− (n=46): mOS 7.5 mo (5.8–12.3) https://t.co/k48dqY829t

4/8 DENALI Part 1b, azenosertib 400 mg 5 days on/2 off: n=102 PROC, median 3 prior lines, 91% prior bev, 55% PARPi, 15% MIRV. Cyclin E1 IHC+ in 51% of evaluable tumors vs CCNE1 amplification in 31%. https://t.co/Fj6tVC5W50

3/8 Next: MAESTRA3 (NCT07797283), a phase 3 of INCB123667 + bev vs bev as first-line maintenance in cyclin E1-overexpressing EOC, starts in 2026. Cyclin E1 biology is heading to the front line.

2/8 INCB123667 + bev in PROC, n=23: 87% cyclin E1 overexpressed (35% of those CCNE1 amplified), 43% with ≥4 prior lines, 83% prior bev. ORR 48% (confirmed 43%) DCR 91% mDOR 5.7 mo mPFS 7.4 mo https://t.co/dXGJFhswAK

https://t.co/Iq3SqHwULK

@ThomasW35874311 The role of surgery in advanced lung cancer. Pushing the boundaries…. All about selecting the right patient. It was intriguing to hear views that would challenge uk practice. @BTOGORG #ESMO26 https://t.co/5z5ug2o7cX

Local therapy in advanced lung cancer at #ESMO26: 💊 Med onc: complements systemic therapy, select responders at 6 to 12 months 
☢️ Rad onc: SINDAS positive in EGFR+, NRG-LU002 negative with IO 
✂️ Surgery: safe and feasible in selected oligometastatic NSCLC https://t.co/OSPwOKTaMJ

This further #ESMO26 @ESMO_Open simultaneous publication is very important for me. @SanRaffaeleMI @MyUniSR Outcomes of pts with MIBC who decline RC in perioperative setting: Take-home message: 1. cCR (Milan criteria) is a reliable biomarker and indicator of outcomes with Systemic Rx and reTURBT 2. Pts who do not get cCR could have a very poor prognosis under bladder-saving approaches > intensification with RC/chemoRT is very much needed Looking forward to ongoing trials (eg EV209, EV309). Congrats to the entire team, also getting Best Poster! @OncoAlert @myESMO @CMercinelli @Anto_cigliola @BrigidaMaiorano @urotoday Piacentini Nasso Serafin et al. Outcomes of patients with muscle-invasive bladder cancer who declined radical cystectomy in perioperative therapy trials conducted at San Raffaele Comprehensive Cancer Center - ESMO Open https://t.co/VhOHVA1GWH

Excited to share our #ESMO26 abstract on emerging targets in mRCC. Analysis of 2,134 RCC transcriptomes identified immunogenic (GPR65/HPK1) and angiogenic (ENPP3/CD70) programs linked to improved outcomes with IO vs non-IO therapy, informing future combination strategies. https://t.co/KlshMfrKv8

Presenting rising star @RashadNawfal post-doc MD in our group working on novel liquid biopsy methods for non-invasive profiling of cancers! Come on down! #ESMO26 @DanaFarber_GU @DanaFarber Also applying for IM match! Don’t miss on him ! @OncoAlert @SylvanBacaLab #MattFreedman https://t.co/gZ62R4t6bI

Cancer vaccines in addition to existing treatments in ovarian cancer #ESMOAmbassadors #ESMO26 @myESMO https://t.co/BWXOehreoy

@myESMO 1st Gyn Session is here! Let's start with cervical cancer. Tisotumab vedotin set the bar in innovaTV 301 (cORR 17.8%, mPFS 4.2 mo, OS HR 0.70). At ESMO, JSKN033, a subQ co-formulation of a biparatopic HER2 ADC + PD-L1 inhibitor, in pretreated cervical cancer (75% prior IO). At RP2D 8.4 mg/kg: ORR 52.9%, DCR 94%, mPFS 8.2 mo. ORR 56% in HER2 IHC 0 and 48% after prior IO. SHR-A2102, a nectin-4 ADC (topo-I payload), after platinum (78% prior IO, ≤2 lines). At 6 mg/kg: cORR 47.2%, DCR 89%, mPFS 7.0 mo, mDoR 7.1 mo. G≥3 TRAEs 53% (mostly heme), no discontinuations. Phase 3 underway. #gyncsm#gyncsm Two nectin-4 ADCs now in cervix. CRB-701 (MMAE, ASCO 2026): cORR 34%, keratitis the main issue. SHR-A2102 (topo-I, ESMO 2026): cORR 47% at 6 mg/kg, myelosuppression the main issue. Populations differ (median 3 prior lines vs ≤2), so we need randomized data.

#ESMO26 Our trial of the #KRAS vaccine 💉presented today alongside concurrent publication in @NatureMedicine! The RAS-revolution continues. Excited about future development, role of ctDNA, and combinatorial strategies. G12D R V S A C & G13D @OncoAlert https://t.co/TbxcUK8Tg3 https://t.co/wnH47HBMMw

#Surufatinib + PlatEtop + serplulimab in epNECs @myESMO #ESMO26 #ESMOAmbassadors https://t.co/5sodZuPhr9

Iza-Bren is a promising ADC, but its toxicity profile looks challenging. Hematologic toxicity is notable, so prophylactic G-CSF may be worth considering. Non-hematologic toxicities, such as nausea, diarrhea, and stomatitis, also appear more frequent than with TPC. #ESMO26 https://t.co/Jx52kjslZI

“Prespecified descriptive OS analysis.” Those words should give us pause. Calling this a “positive OS result” in a phase 3 trial manuscript is misleading when OS was outside the formal testing strategy. The results are encouraging, but an OS benefit has not been formally demonstrated in this analysis. I’m surprised this framing passed journal review. Oncologists and patients shouldn’t need to close-read a manuscript like English professors to understand whether a trial formally demonstrated an OS benefit. Put the bottom line up front. @Timothee_MD @oncology_bg @SusanGKomen @BCRFcure @OncoAlert @Annals_Oncology @myESMO @ASCO @AACR @SABCSSanAntonio

#ESMO26 HERIZON-GEA-01 @myESMO @OncoAlert https://t.co/nVPMS1M3lg https://t.co/3IRy2uOlEW

@tonichoueiri with med onc pearls for neoantigen mRNA vaccines. The future is happening now — esp w readout of INTERPATH-001 trial this #ESMO26 @myESMO @oncoalert https://t.co/EhNz2A40yG

#ESMO26 Optimal duration of adjuvant endocrine therapy: 5, 7–8, or 10 years? From Dr. Fumikata Hara’s excellent discussion👇 https://t.co/BHXSGesayf

mRNA vaccines - what medical oncologist should know? Nice talk by @DrChoueiri @myESMO #ESMO26 . Personalized mRNA cancer vaccines used along with existing treatment options like immunotherapy is the next frontier in cancer treatment. @OncoAlert https://t.co/n47EvAyfYC

Excellent perspective from @DrChoueiri The more personalized the vaccine, the bigger the system it needs. Melanoma shows promise. Proud our @Ankaratip1945 team is part of a kidney cancer vaccine trial. @myESMO @OncoAlert @OpenMedicineHQ #ESMO26 @DanaFarber @DanaFarber_GU https://t.co/lR83gEplV0

💉 #ESMO26 mRNA cancer vaccines: beyond melanoma Personalized neoantigen vaccines are moving from treatment toward broader (and earlier) disease settings! 💥 Signals in low-TMB tumors 💥 Activity explored in PDAC and RCC 💥 Now even entering cancer prevention in Lynch syndrome The mRNA “message” getting much broader than melanoma 😏 Congrats @DrChoueiri!! Amazing discussion!!! 👏🏼 @OncoAlert @OncoReporte @myESMO @_SEOM @GrupoMelanoma

Have you ever wondered what #ESMO26 presenters see when they are at the podium? @myESMO @OncoAlert https://t.co/CChs7xkynZ

NATALEE 6-y results are out! #ESMO26 2.1 delta in survival at 6 years. Thanks @Annals_Oncology for reporting subsequent therapy data! 👉Only 44.4% of control arm patients with distant recurrence received a first-line CDK4/6i Does this survival difference truly inform clinical practice in settings where CDK4/6i are standard of care for metastatic disease? In my opinion, the answer is no.

Look forward to INTerpath NSCLC trial data, especially in stage I. Neoadj ICI better than adj ICI, but when we miss this window INT could be a great option. Also, maybe ICI+INT works well on micrometastatic cells that haven’t yet built an immune exclusive TME around themselves. https://t.co/IXcKC1gN36

Looks like the discussant is on my side too, Amol! 😉 We acknowledge the limitations of the nominal p-value, but I think it would be unfair to judge ribociclib’s clinical benefit solely on that basis. https://t.co/gQtuwasEEp https://t.co/absCmwDmqD

Join me at posters #ESMO26 @myESMO - presenting investigator initiated trial #BOOSTRCC PCSK9 inhibitor evolocumab + nivo in IO refractory #kidneycancer. Grant supported & pt who benefited had higher spread HLA expression after tx. @oncoalert @tonichoueiri @montypal @albigesL https://t.co/UUrR5CIfSw

@dr_yakupergun can u suggest me a good magnifying glass ? Asking for a friend 😀 @myESMO #esmo26 As expected, no one talks about nominal p value. https://t.co/aGWpPg4U4M

#ESMO26 Today, we’ll probably spend most of our time discussing NATALEE! At 6 years, OS: 91.9% vs 89.7% (HR 0.81; nominal p=0.019). BCSS benefit is also encouraging (HR 0.71). https://t.co/3H1TT3GeU2 https://t.co/QUvtNqcwcK

NATALEE: OS data Adjuvant ribociclib in ER+ breast cancer 6 yr OS HR 0.809 (delta 2.1%) BCSS: 0.706 (delta 2.6%) 6 yr iDFS HR 0.741 (delta ~5%) DDFS: HR 0.744 @OncoAlert #ESMO26

ctDNA analysis from the EVP vs chemotherapy muscle invasive bladder cancer trial (B15/EV304) shows ctDNA is strongly prognostic at all time points for both arms. EVP has higher clearance rates across time points, underlining its ⬆️ activity. Results for the control arm are strikingly similar to the ctDNA results in the chemo control arm in the NIAGARA trial. This consistency underlines the utility of ctDNA from a prognostic perspective.#ESMO26 @OncoAlert

💉#ESMO26 Personalized cancer vaccines: promise meets precision (🗣️ Dr. Patrick Ott, he is simply the BEST!!!!!!!!) Large-scale personalization is now feasible, with growing clinical evidence in melanoma 💥 -Robust, durable vaccine-induced T-cell responses -Positive randomized phase II/III development in adjuvant melanoma -Excellent safety profile -But immune breadth remains limited Personalized? Yes. Predictable? Not yet @OncoAlert @OncoReporte @myESMO @_SEOM @GrupoMelanoma

Perioperative EV + Pembro momentum by #DrAndersUllen in KEYNOTE-905 Ph.III ad hoc analysis of cis-ineligible MIBC. 2-yr EFS: 75.8% EV/Pembro vs 55.8% Pembro vs 41.0% surgery alone. EFS HR 0.40 vs 0.71 (each vs control). pCR 58.8% vs 25.3% vs 10.3%. #ESMO26 #BladderCancer @myESMO @OncoAlert

#ESMO26 🚀 RASolute 302 | Phase III 👥 500 pts | Previously treated mPDAC 💊 Daraxonrasib (RAS(ON) inhibitor) vs chemo 📈 OS: 13.2 vs 6.7 mo (HR 0.40) 🧬 OS benefit by RAS genotype: 🔹 G12D: HR 0.49 🔹 G12V: HR 0.32 🔹 G12R: HR 0.61 📊 PFS: HR 0.55 (BICR) 🎯 ORR: 32% vs 11% 💡 new SOC! @OncoAlert

The KN905 MIBC trial includes a 3rd, less celebrated arm of single agent pembro. Results show pembro delivers an important contribution to the EVP. The trial is small and EVP performs better, but pCR rates for pembro of 35% are in the same range as neoadjuvant cisplatin chemo while EFS/OS HRs of 0.71/O.76 vs surgery are impressive. Pembro had about half the toxicity of EVP, underlining the relevance of therapy duration. VOLGA (3 cycles of EVD), is a half way between Pembro alone and 9 cycles of EVP. @Annals_Oncology #ESMO26 @Annals_Oncology @OncoAlert

Caveats: ctDNA % drives sensitivity, and deletions are hardest. PTEN loss is spatially heterogeneous, with discordance both ways, so neither tissue nor plasma is a gold standard. PTEN loss in ctDNA only → worst OS (mOS 11 mo). Matched WBC DNA is a must: 10 "hits" were CHIP. 2/2 https://t.co/Qdfx6jaien

SANO 5-year update, #ESMO26 LBA78. 
Some surprises. Study Design: Surveillance vs surgery after cCR to CRT in locally advanced esophageal cancer (n=309). 5-year OS ~50% vs 54% (NS), HR 1.17 (95% CI 0.77–1.77) 
Distant mets 46% vs 29% (P<.01). This met rate is higher and now significant. Reminder: only 41.4 Gy/23 fx. A pre-op, arguably non-definitive dose, especially with ~75% adenocarcinoma. Does this apply in the DFLOT + post-CROSS era? Either way, upper GI harder to tackle non-op than hoped. @OncoAlert @TheGutOncLab @Onco_Nexus

Honored to start my commitment as #ESMO Faculty for Non-metastatic NSCLC and other thoracic malignancy for the period 2026-2030. Like never before, hope is here for all patients with thoracic cancers. #ESMO26 https://t.co/mWvR0KrcVO

🔥 #ESMO26 Matchmaking TCRs: from standard fit to bespoke melanoma care The antigen is as important as the engineered T cell. Finding the right cell may start with finding the right match @OncoAlert @OncoReporte @myESMO @_SEOM @GrupoMelanoma https://t.co/YvXoySJxyo

Always interesting to see people come up to the microphone with wild very broad questions that aren’t necessarily on topic. 😳. So tough as a moderator to address these #ESMO26 I’m not disagreeing with what said… but. #Breastcancer

The triplet of SG (TROP2 Topo1), EV (Nectin4/MMAE) and PD-1 triplet therapy has a response rate of 81% in 21 patients in advanced bladder cancer. Complimentary targets and payload make sense . These data should br taken forward in muscle invasive and advanced disease. Strategies to manage toxicity in bladder cancer is essential #ESMO26 @myESMO @OncoAlert

So no one knows why Durvalumab worked and Pembrolizumab and Nivo failed in perioperative MIBC trials. @DrChoueiri @tompowles1 @HHammersMD @montypal @OncoAlert @myESMO #esmo26 https://t.co/3kilxJWJnB https://t.co/xf4MDnwcxJ

We are delighted to present 2 data sets at #ESMO26 - #AVCT Trials in Progress with AVA6103 shows some critical platform data showing mechanistic evidence for fibroblast recruitment, rapid and deep tumor penetration and enhanced payload exposure over traditional ADC #LetsDoThis https://t.co/zFCbZo9nho

Fantastic summary slide of metastatic #bcsm #ADC landscape by @BarbaraPistill2 in her #ESMO26 discussion #ESMOAmbassadors @OncoAlert What do we need next??? 📍novel payloads 📍novel targets 📍data on sequencing https://t.co/AlbwYGRHP0

Important caution for ctDNA-guided bladder preservation in MIBC: Patients who clear ctDNA have better outcomes, but ~25% who convert from ctDNA+ to ctDNA− still experience progression despite cystectomy. ctDNA clearance ≠ cure. Prospective validation is essential. #ESMO26 @OncoAlert

An increasingly crowded ADC landscape in HR+/HER2− mBC, with multiple positive trials but unanswered questions about optimal sequencing. From Dr. Babrara Pastilli’s excellent discussion at #ESMO26 https://t.co/5wLSXrSg6X

It hard to explain why 1 trial with gem/cis +/-PD(L)1 (NIAGARA) is +ve for EFS/OS and 2 very similar trials (presented today) are negative in MIBC. Potentially NIAGARA has the highest risk population, not all respond to IO and the maintenance phase the most effect- but the OS of gem/cis pembro HR of 1 is concerning. This reflects what we saw in metastatic disease with contradictory results for the big combination trials. Overall EVP looks better and more consistent #ESMO26 @myESMO @Annals_Oncology @OncoAlert

Building on @DanaFarber_GU and @BradMcG04 DAD trial of EV/SG and adding PD1 shows ORR 81%. 1 PD with shrinkage ! Triplet therapies comping in bladder cancer ! Stay tuned for DAD-IO open @DanaFarber_GU @DanaFarber @myESMO @OncoAlert #ESMO26 https://t.co/p4CbQasaxB

Three HER2-targeting ADCs in HER2-low breast cancer. Same target, same linker, same payload class (TOP1 inhibitors). Three ADCs superior to chemotherapy. Three me-too ADCs??? https://t.co/slDB7fjMte

Two amazing Chinese breast cancer trials presented #ESMO2026 #ESMO . China is now a powerful and very welcome ally in the world-wide anti-cancer effort.

5 phase III perioperative MIBC trials, with differing results. EV-303, EV-304 and NIAGARA improved EFS/OS, while ENERGIZE and KEYNOTE-866 did not meet their EFS endpoints. Important differences in patient populations, regimens and trial design. Cross-trial comparisons require caution. #ESMO26 @OncoAlert

Encouraging OS results in neuroendocrine prostate cancer at #ESMO26! #KEYNOTE-365 evaluated pembrolizumab + carboplatin/etoposide vs chemotherapy alone. • mOS: 10.2 vs 7.1 months (HR 0.33) • rPFS: 5.1 vs 4.0 months (HR 0.66) • PD-L1 CPS ≥1: mOS 11.0 vs 4.8 months (HR 0.16) No new safety signals observed. @myESMO @oncoalert

🎯 #ESMO26 ENERGIZE ph3 trial presenting by @AndreaNecchi other periop of IO therapy in MIBC! Cis-Gem + Nivo vs Cis-Gem! Other negative study of IO + cisplatin-based chemo!🧐 Reinforce the value of ADC + Pembro in this setting! @OncoAlert @myESMO @GuardConsortium @PGrivasMDPhD @apolo_andrea

Is this the end of platinum-based chemo + immunotherapy in #bladdercancer? 🤔 What should we do with NIAGARA from now on? 😬 @OncoAlert @myESMO @OncoDailyGU #ESMO26 https://t.co/IF0qJTrz5Q

🇨🇳HORIZON-Breast06: Trastuzumab rezatecan widely outperformed chemo in endocrine-refractory HR+ MBC (PFS 16.6 vs 6.8 months, HR 0.25, p=0<0.01). Definitely passes the truck test. No significant OS, likely due to crossover of some patients to TOPO1 ADCs. #ESMO26 #ESMOAmbassadors https://t.co/u7TsssjoiN

Probably first negative trial for Trastuzumab deruxtecan. Talent trial. For early stage HR positive Her2 low EBC @myESMO #esmo26 @OncoAlert https://t.co/1m62ih9PrE

Full house for Bladder/RCC updates first with #KN866 #ESMO26 Gem/cis in MIBC + placebo or pembro (➖) study & less relevance in the era of EVP SOC Vs similar trial NIAGARA was ➕ pCR 44.4% vs 35.8% EFS & OS not significant We wait #VOLGA tomorrow for more in this space https://t.co/uSLgxYSoMO

#ESMO26 🧬 G-HOPE-001 | Phase III 👥 460 pts | CLDN18.2+ G/GEJA, ≥3L 💊 Arcotatug tavatecan (ADC) vs TPC 📈 PFS: 7.1 vs 3.1 mo (HR 0.45; updated) ⏳ OS: 10.2 vs 6.9 mo (HR 0.57; p<0.0001) 🎯 ORR: 37.4% vs 7.7% 🚀 Significant PFS & OS benefit! @OncoAlert https://t.co/hVpdupeq2c

94% response rate. 100% intracranial response. 🤯 ROS1+ lung cancer may be getting a new frontline contender. Dr. @alexdrilon 🇺🇸breaks down ARROS-1 in under a few minutes 🎥👇 Must-watch for anyone treating #LCSM 🫁 #Podium2Screen #OncoAlert Presented at #WCLC26 and video release for #ESMO26

G-HOPE-001 phs-3: Arcotatug tavatecan vs TPC in previously treated G/GEJA: First interim analysis #ESMO26 #ESMOAmbassadors 🇨🇳🇯🇵, 2600 prescreened, 430 included 👉ORR: 37 vs 7.7% 👉 mPFS: 7.1 vs 3.1 mo 👉 mOS: 10.2 vs 6.9 mo 🧐CLDN-2 ADC, strong signal of efficacy, acceptable safety @myESMO @ASCO

Mechanism wise there has got to be a bi-directional crosstalk between wild type RAS and PRMT5 First Daraxonrasib has greater ORR than Zoldonrasib per press release, and second: “and partly because targeting PRMT5 may attenuate some of Rasonque’s toxicities”

Tango reports 82% tumor response rate in trial of combo therapy (Daraxonrasib plus vopimetostat) for advanced #PancreaticCancer at #ESMO26 https://t.co/iaYLkWsnsl Reduced toxicity data is particularly important as a lower Daraxonrasib dose can be used.

Phase II SARON (n=140,NSCLC): ​Consolidation RT + 1L SACT improved: • PFS: 13.9 vs 8.9 mo (p=0.03) • 12-mo local failure: 13% vs 39.5% (p<0.01) ​No OS benefit (31 vs 28 mo; p=0.95). Grade ≥3 toxicity: 28.6% both arms. ​#ESMO26 @Larvol @OncodailyLung https://t.co/99mkC2CR2j

MASTERPLAN (#ESMO26 , n=74): SBRT + chemotherapy vs chemotherapy alone: 🔹 Median OS: 22 vs 14 months 🔹 Median PFS: 11.9 vs 6.3 months 🔹 12-month locoregional recurrence: 20.2% vs 52% Promising phase II results; confirmation needed. #ESMO26 @OncoDailyGI @larvo https://t.co/ONPhAVgL9P

I note of skepticism that the the adjuvant individualized neoantigen therapy data is not meaningful progress In case of NSCLC- we shall learn as there are 3 separate studies ongoing (one just completing accrual!) But scientifically… Neoadj IO works better compared to adj IO as activated T cells need to see the “in situ vaccine” of the native tumor for long-standing benefit. Postop in micromet setting simply stated there is just no cancer cells to work with- as an analogy, for T cells to build muscles they need machines in the gym… otherwise, no lifting- no muscle… Now the beauty of INT is that it does provide an excellent gym with the best tailored neoantigen weight machines for the immune system to work with! So w results of Interpath-001 i’d say- T cells and all of us, lets go to the gym and Cheers on a first set of great results!

#ESMO26 Comparable sensitivity and safety fir at home HPV self collection https://t.co/qbGVquQfTD

One of the best things about #ESMO26? Reconnecting with great friends and inspiring colleagues! Wonderful to catch up with @g_mountzios. Different journeys, one shared ambition: improving our patients’ lives and working towards a future where we can cure cancer. Science brings us together. Friendship makes the journey even better! 💙 #ESMOAmbassador #ESMO26 #Oncology #LungCancer #CancerResearch

Everything at ESMO is sponsored by pharma companies, even the WiFi https://t.co/Rh1U9fqIkZ

Opening ceremony at #ESMO26 #ESMO26 #ESMOAmbassadors #ESMOcommunity @myESMO https://t.co/vl7KEIRObE

Opening Ceremony at @myESMO #ESMO26 with the ESMO Award Ceremony #NoemiReguart, chair of Nomination Committee presents all awardees Congrats to all 👏🏻👏🏻👏🏻 #ESMOAmbassadors https://t.co/g2tMu7XVHP

🚨 ESMO 2026 | TOP 10 GYNAE ONCOLOGY TRIALS TO WATCH! From chemotherapy-free immunotherapy to next-generation ADCs, #ESMO26 could reshape gynaecological oncology! 🔥 My Top 10, by cancer subtype: 🔴 ENDOMETRIAL CANCER TroFuse-005 (LBA11) | Sacituzumab tirumotecan vs physician’s choice in recurrent/advanced disease. KEYNOTE-C93 (LBA12) | Pembrolizumab alone vs chemotherapy in 1L dMMR disease. Can we omit chemotherapy? NRG-GY020 (1239O) | Adjuvant radiotherapy ± pembrolizumab in early-stage dMMR disease. Sacituzumab tirumotecan + pembrolizumab (1259P) | ADC + immunotherapy in post-platinum pMMR disease. 🔵 OVARIAN CANCER BEHOLD-1 (LBA41) | Mocertatug rezetecan, a B7-H4 ADC, in platinum-resistant disease. REJOICE-Ovarian02 (1247RO) | Raludotatug deruxtecan + bevacizumab in platinum-resistant disease. REJOICE-Ovarian01 (1331P) | Updated efficacy and safety of raludotatug deruxtecan. BEHOLD-1 biomarker analysis (1248RO) | Which biomarkers predict response to B7-H4 ADC therapy? 🟣 CERVICAL CANCER CALLA (LBA45) | Tisotumab vedotin + pembrolizumab vs chemotherapy in recurrent/metastatic disease. EMPOWER-Cervical 1 (1250O) | Cemiplimab-based strategies and long-term outcomes. ⭐ My top 3 to watch: KEYNOTE-C93 | TroFuse-005 | BEHOLD-1 Which trial has the greatest potential to change your practice? @ESMO_open @myesmo @ASCO @oncoalert #ESMO26 #GynOnc #Oncology

🚨 #ESMO26 Lung Cancer: the 10 studies that best capture where the field is moving @OncoAlert What stands out to me from the @OncoAlert faculty selection is how much the lung cancer landscape is shifting toward smarter sequencing, biomarker-defined combinations, and more selective treatment intensification. 🫁 Top Ten from Madrid: 1️⃣ DeLLphi-305 — tarlatamab + durvalumab in 1L ES-SCLC maintenance 2️⃣ Krascendo 1 — divarasib vs sotorasib/adagrasib in KRAS G12C NSCLC 3️⃣ SAFFRON — osimertinib + savolitinib after osimertinib in EGFRm/MET+ disease 4️⃣ OptiTROP-Lung04 — sac-TMT after EGFR-TKI 5️⃣ OptiTROP-Lung06 — sac-TMT + pembrolizumab in PD-L1-negative NSCLC 6️⃣ PERSEE — pembrolizumab ± chemotherapy in PD-L1 ≥50% 7️⃣ SANOVO — savolitinib + osimertinib in 1L EGFRm/MET-overexpressed NSCLC 8️⃣ IFCT-2103 DIAL — continue pembrolizumab vs observation at 6 months 9️⃣ PANKU-Lung01 — iza-bren after third-generation EGFR TKI 🔟 SARON — consolidation RT in oligometastatic NSCLC 🎯 Why this matters: these studies are not just adding new drugs. They are refining when to intensify, when to combine, when to continue, and when biology should drive the next step. That is the real value of a “Top Ten” list: not more information — better prioritization of the data most likely to influence practice. @christine_lovly @GlopesMd @DrSanjayPopat @StephenVLiu @jillfeldman4 @UOzkerim @DrMirallas @CharuAggarwalMD @peters_solange @JordiRemon #lcsm #OncoAlert #ESMO26 #LungCancer #NSCLC #SCLC #PrecisionOncology

From all the social media reaction to yesterday’s embargo break I get the impression everyone expected a cure for melanoma. These patients had already had their melanoma removed. They were cancer-free. The whole question was who stays that way. These are the numbers: 82% of the vaccine group had no recurrence, against 70% without. And the part being missed everywhere: the comparison wasn't vaccine versus nothing. Everyone got immunotherapy, already the most effective treatment we have in melanoma. The vaccine had to improve on something that already works well. That's a much harder test than most drugs ever face, and it's exactly why the number looks smaller than people hoped. But this wasn’t about one drug that ends cancer, but treatments stacked on treatments until a disease that killed most people kills fewer. Nobody cured melanoma this week. A therapy built individually for each patient gave a proof of concept, not a cure for everything, but that wasn’t the goal to begin with. For many (future) melanoma patients this is still a big win. Now we need to make this progress scalable for each patient around the world.

Today at #ESMO26, the 6-year results of NATALEE will be presented. Ahead of the presentation, my personal view on the survival gains with adjuvant CDK4/6 inhibitors… The 6-year OS rates in NATALEE were 91.86% vs 89.73%: an absolute gain of 2.1 percentage points (HR 0.809; 95% CI 0.661–0.989; nominal one-sided p=0.019). The absolute 7-year OS gain in monarchE was 1.8 percentage points (HR 0.842; p=0.027). I do not think these gains should be dismissed as “only 2%.” In the EBCTCG analysis, adding taxanes to anthracycline-based chemotherapy—an approach we have accepted as standard for years—provided an absolute 5-year OS gain of approximately 1.9 percentage points. The populations and follow-up periods differ, so we cannot directly compare treatment efficacy. However, the standards we use to judge a few percentage points of survival benefit should be consistent. Moreover, 95.4% of patients in monarchE had already received chemotherapy. This survival gain represents an additional benefit on top of chemotherapy and endocrine therapy. Patient selection, toxicity, treatment duration, and cost certainly deserve discussion. However, the survival benefit of adjuvant CDK4/6 inhibitors in appropriately selected patients should not be underestimated.

Lovely walking tour & sunset in Madrid @myESMO #ESMO26 Looking forward today to: #VOLGA peri-op durva/treme/EV MIBC & Daro in very high risk PCa both in presidential session🌟 #KNB15 ctDNA analysis Claudin-6 ADC in GCT #CAPITELLO281 capi OS in mCSPC NAT ICI in penile CA https://t.co/p31vBubCOj

#ESMO26 | HERIZON-GEA-01 – Updated OS Her2 positive gastric/ge cancer At 35.3 months of follow-up, zanidatamab + CT now shows a significant OS benefit over trastuzumab + CT: 22.9 vs 19.6 months (HR 0.76; p=0.0088). With the addition of tislelizumab, median OS increased to 27 months, but the additional benefit was statistically borderline (HR 0.81; p=0.0502). Considering toxicity, we need to carefully analyze which patients should receive the triplet regimen.

From Berlin to Madrid! 🇩🇪➡️🇪🇸 Great to start the morning with James Larkin as we kick off #ESMO2026. Passing the mantle from @MyriamChalabi and me (#ESMO25) to James and @YJanjigianMD for the new scientific program—excited to see what they bring to life! Shared purpose, lasting friendships, and better care for our patients. @myESMO @FAndreMD @curijoey @FedefedeFri @OncoAlert

Some thoughts on the INTerpath-001 backlash, and the simplistic "neoadjuvant already does better, so why bother" take. I think it misses a few important things. ➡️ First, the neoadjuvant data (S1801, NADINA) come from patients with macroscopic, clinically detectable nodal disease. INTerpath-001 also includes node-negative IIB/IIC and patients whose nodal disease only showed up on sentinel node biopsy. In the big SLN trials, about two thirds of SLN+ patients had deposits ≤1 mm. None of these patients are neoadjuvant candidates. We see the same confusion in #NSCLC all the time, when people compare stage IIIA from adjuvant trials (pathological staging) with stage IIIA from neoadjuvant trials (clinical staging). Same stage on paper, not the same patients. ➡️ Second, INTerpath-001 was designed before NADINA read out, when adjuvant anti-PD-1 was still the default for resected stage III. Judging it against today's practice is a bit of hindsight. ➡️ Third, I suspect the most logical place for a neoantigen vaccine is after neoadjuvant ICI in patients who don't reach pCR. INTerpath-009 is already testing exactly this in NSCLC, so we'll get some hints there. ➡️ And all of this comes with only an absolute ~3% increase in grade ≥3 toxicity, which also belongs in the balance. For macroscopic stage III, the critique lands. I want to see the full data and the stage breakdown at LBA1. But I'd be careful firing at this result before we've even seen it properly. @OncoAlert @Larvol @KolPulseAI @_SEOM @myESMO #Melanoma #ESMO26

First day at #ESMO26! Exceptional international faculty @EnriquetaFelip, Dr. Antonio Passaro, @MARIANOPROVENCI and Maria Karen, exploring the many facets of NSCLC management, always keeping patients’ preferences at the heart of decision-making. Full house at #ESMO26! https://t.co/7EGMyWSSQs

これは癌腫臓器横断的な承認で、大きいニュースです。我々のESMOの口頭発表ではC-CATとUCSDのデーターで、TMB16が最も良いcutoffで、TMBの10-16のICIの効果が乏しいことを臨床的かつ生物学的に示しています。今まで当たり前と信じられたきたことを見直す視点の大事さを学びました。 @Dr_R_Kurzrock https://t.co/QHHVteWilt

#ESMO26 | NSABP B-42 – 15-year final analysis After 5 years of AI-based therapy, an additional 5 years of letrozole: • DFS: 61.6% vs 56.5% (HR 0.85). • Distant recurrence: 6.9% vs 9.7% (HR 0.72). The sustained reduction in distant recurrence is valuable. Given changes in post-recurrence treatment over such a long follow-up, I do not consider OS alone decisive. However, SALSA did not demonstrate superiority of 10 over 7 years, nor did IDEAL demonstrate superiority of 10 over 7.5 years. B-42 compares 5 with 10 years. Several questions remain: • In which patients is 10 years superior to 7–8 years? • Should we go beyond 10 years? • When adjuvant CDK4/6 inhibitors are added, should we still extend endocrine therapy for this long? Personally, I favour extending treatment to 10 years, particularly in patients at high risk of late recurrence who tolerate therapy well, and perhaps longer in selected patients.

As we reflect on the @moderna_tx adjuvant vaccine data I wanted to remind all @myESMO @sitcancer @ASCO the force that was Jeffrey W Weber @nyulangone - we will all feel his presence as data are presented. True mentor, leader, friend. https://t.co/TPDGXqCc0L

Topline ESMO data from INTerpath-001 (#Moderna's personalized cancer vaccine) reportedly leaked elsewhere: RFS HR 0.58 (Honestly shame on people for breaking embargo’s). There is a huge divide here between physicians and non-physicians on the outcome. To me, this was huge and clearly worked. This hazard ratio puts it in the company of the most paradigm-changing adjuvant trials in oncology history. Yes, the same outcome can be generated from giving pembro in the neoadjuvant space [SWOG S1801 neoadjuvant + adjuvant pembro vs adjuvant pembro alone: EFS HR 0.58.] That isn't the point. A peptide vaccine strategy yielded the same outcome as having a tumor in vivo. This demonstrates the tech worked, now it can be applied more broadly or potentially even supercharge the neoadjuvant space with less immunogenic tumors. Time to do better and apply to more things (like colon cancer pls). #ESMO26
@OncoAlert @TheGutOncLab

🚨‼️ Saved this one for the start of #ESMO26! If melanoma/skin cancer is your field, these are the 8 trials I think you really cannot miss in Madrid 💥 The studies, the timing, and why each one matters: all in one picture! Your melanoma map for Madrid starts here🗺️ @OncoAlert @OncoReporte @myESMO @_SEOM @GrupoMelanoma

#ESMO26 | HORIZON-Breast06 HER2-low mBC after ≥1 prior line of chemo for metastatic disease, or in the first-line chemo setting after prior ET (if HR+). Trastuzumab rezetecan vs. physician’s choice of chemo PFS: 16.4 vs 6.8 mo (HR 0.27) ORR: 75.5% vs 41.2% Grade ≥3 TRAEs: 84.1% vs 67.9% ILD: 2.5%.

🚀Upper GI oral abstracts #ESMO26 Day 1 summary results 1) Arcotatug tavatecan improved PFS in CLDN18.2+ G/GEJA in the 3L+ setting 2) SANO trial, OS at 5 years similar between active surveillance and surgery in patients with oesophageal cancer and a complete clinical response after nCR, despite more distant metastasis 3) Adding pembrolizumab to dCRT did not improve EFS in untreated unresectable esophageal or GEJ cancer with PD-L1 CPS ≥10 4) Daraxonrasib demonstrated consistent OS benefit in different RAS mutatin subgroups in RASolute-302 5) mKRAS-specific lymph node targeted amphiphile immunotherapy in PDAC did not met primary DFS endpoint. 6) Zani + CT +/- tisle keep OS benefit in at IA2 of HERIZON-GEA-01 7) Anbenitamab plus ChT improved OS in patients with HER2-positive GC/GEJC adenoca after previous trastuzumab 8) TQB2102 (HER2 bispecific antibody-drug conjugate) plus bemotrizumab and capecitabine demonstrates promising antitumor activity in 1L of advanced GC/GEJC 9) Dostarlimab in Pts with localized dMMR/MSI-H GEA led to a 62.5% 1y-cCR at the first interim analysis, enabling organ preservation. 10) FOLFIRI and Ram vs paclitaxel in taxan-pretreated GEA imporved PFS but no OS 11) Stage II–IIIB gastric cancer after D2 resection, four months of adjuvant XELOX was noninferior to six months for 3-year DFS 12) Adding durvalumab to dCRT in locally advanced esophagus carcinoma did not improve PFS 13) Adding SBRT to MFOLFIRINOX in high risk, borderline resectable or locally advanced pancreatic cancer mproved LRR and PFS 14) FGFR2b expressing GC/GEJ with co-existing FGFR2 amp may define a biologically distinct subset with potential sensitivity to bemarituzumab #cancer #oncology #MedX #GI #gastrointestinal @OncoAlert

🚨 Scientific embargoes exist for a reason: fair access to data, scientific integrity and, ultimately, patients. Seeing a major #ESMO26 study disclosed ahead of schedule is disappointing. I think ESMO takes its embargo policy seriously, and I would expect a breach of this magnitude to have consequences. Science should set the timeline, not the stock market 😡 With INTerpath-001, someone clearly took a shortcut on the path to the data. @OncoAlert @OncoReporte @myESMO @_SEOM @GrupoMelanoma

🧿 Shaping the future of #NSCLC at #ESMO26 Delighted to co-chair today’s symposium in Madrid with @MARIANOPROVENCI, Enriqueta Felip & Marcia K. Horn @Exon20Group Translating scientific advances into better outcomes for patients, today and tomorrow. https://t.co/H7uCrYlTuD

🚨 #ESMO26 | Phase III INTerpath-001 🚨 After an early embargo breach, @myESMO brought the abstract release forward!!!!!! And yes, it’s clearly positive: 📉 RFS HR 0.58 📉 DMFS HR 0.62 But here’s the uncomfortable part: SWOG S1801 also reported an HR 0.58…simply by moving 3 doses of pembrolizumab BEFORE surgery… ☝🏼Not the same population. Not the same endpoint. Not a cross-trial comparison. Still, in 2026, should a personalized mRNA vaccine really be benchmarked against adjuvant pembro alone? Before calling this a new standard, I want to see the vaccine face the NEOADJUVANT era. Same HR. Different path. And that may be the real INTerpath question 👀 @OncoAlert @OncoReporte @myESMO @_SEOM @GrupoMelanoma What do you think? @SuyogCancer @OncBrothers @A_May_MD @Dr_R_Kurzrock

#ESMO26 | TALENT Neoadjuvant T-DXd showed very low pCR rates in HR+/HER2-low early breast cancer: - T-DXd: 7% - T-DXd + anastrozole: 3% - T-DXd → chemotherapy: 9% We should remember that pCR is a limited surrogate endpoint in HR+ disease. However, these results do not support T-DXd as an alternative to standard neoadjuvant chemotherapy. Moreover, given the heterogeneity of HER2-low disease, I find it unsurprising that the success of T-DXd in the metastatic setting does not translate into similar outcomes in early-stage disease, despite the lower tumor burden.

#ESMO26 | NATALEE – 6-year results (Pre-presentation abstract) 6-year OS: 92.73% vs 89.38% (HR 0.809; nominal p=0.019). iDFS: HR 0.741; absolute benefit of 4.1% at 6 years. In monarchE, a 7-year OS benefit was demonstrated (HR 0.842; p=0.027). NATALEE also shows a promising OS signal; however, formal statistical significance has not yet been established. Looking forward to the presentation....

#ESMO26 | LBA79 Second interim analysis from Ph3 HERIZON-GEA-01 Overall survival ▪️Zani + chemo vs Tra + chemo: 22.9 vs 19.6 mo, HR 0.76, p=0.0088 ▪️Zani + Tis + chemo vs Zani + chemo: 27.0 vs 22.9 mo, HR 0.81, p=0.0502 @myESMO @OncoAler https://t.co/n8UbjHSTxt

SAFFRON trial ESMO 2026 Osimertinib plus savolitinib after osimertinib resistance in EGFR-mutant NSCLC Phase III trial First Glimpse https://t.co/rAnhPyNkhM

#ESMO26 | LBA77 G-HOPE-001: Ph3 Arcotatug tavatecan (CLDN-ADC) vs SoC in 3L+ CLDN18.2+ GEA ▪️PFS: 5.5 vs 2.9 mo, HR 0.47, p<0.0001 ▪️OS: 9.9 vs 7.4 mo, HR 0.63 ▪️ORR: 23.6% vs 5.3% @myESMO @OncoAlert https://t.co/3vmQypuEip

Holy smokes mOS 22 vs 14 months (p=0.006) @jryckman3 @TonyFelefly https://t.co/gty5hE4P3J

@myESMO @LungCancerRx @OncoAlert @oncodaily 3/ DeLLphi-305 (LBA3), Oct 24, 17:18 CEST Tarlatamab + durvalumab as 1L maintenance in ES-SCLC. Amgen reports an OS win at interim. How large, and can clinics deliver T-cell engager monitoring in maintenance? @LungCancerRx @OncoAlert @oncodaily https://t.co/g8um5k4dwG

1/ My top 7 thoracic picks for #ESMO26 (Madrid, Oct 23–27), ranked. @myESMO 5 of these phase 3s already announced positive toplines. ESMO is where we finally see effect sizes. The question each one answers 🧵 #LCSM @LungCancerRx @OncoAlert @oncodaily https://t.co/fmhhGivXPE

🚨 ESMO 2026 | RASolute 302 (LBA82) Phase III: Daraxonrasib (RAS-ON inhibitor) vs chemotherapy in previously treated mPDAC (N=500). 🔹 Median OS: 13.2 vs 6.7 months (HR 0.40) 🔹 Median PFS: 7.2 vs 3.6 months (HR 0.49) OS benefit by RAS mutation: • G12D: HR 0.49 • G12V: HR 0.32 • G12R: HR 0.61 • Q61: HR 0.37 • No RAS mutation identified: HR 0.43 A remarkable 60% reduction in the hazard of death overall, with consistent directional benefit across RAS subgroups. @myESMO @OncoAlert @OncBrothers #ESMO26 #PancreaticCancer #RAS

🚨 ESMO 2026 | SANO Trial (LBA78): 5-Year Result Active surveillance vs surgery (N=309) 🔹 5-year OS: 50% vs 54% (HR 1.17; 95% CI 0.77–1.77) 🔹 DFS: HR 1.39 (95% CI 0.94–2.06) 🔹 5-year distant metastases: 46% vs 29% (p<0.01) 🔹 43% in the surveillance arm were spared a non-beneficial oesophagectomy. An important organ-preservation strategy, but the higher distant metastasis rate is concerning. Would you recommend active surveillance over surgery for a patient achieving complete clinical response? #ESMO26 #EsophagealCancer #SANO @myESMO @NiuSanford @OncoAlert @OncBrothers

ツチノコ的ESMOレビュー① いきなり情報解禁前にデータが漏れるという大波乱の幕開けです。 モデルナの株価が25%下落の 大・暴・落！！ 個別化mRNAがんワクチン 「intismeran autogene」 の第Ⅲ相試験、INTerpath-001ですね。 すでにデータが世に出てしまったため、ESMOが正式に情報解禁を前倒ししました。 これ、何をやっているかというと、、 患者さんのがんの遺伝子情報を調べて、その人のがんに特有の目印を狙うmRNAワクチンを作る。 それを使って、免疫に 「この目印のあるがん細胞を攻撃してくれ」 と教える治療です。 患者さんごとに作る、オーダーメイドのがんワクチンですね。 今回の対象は完全切除後のStage IIB〜IVの悪性黒色腫の患者さん1,137人。 ①個別化mRNAがんワクチン＋キイトルーダ（Pembrolizumab） ②キイトルーダ単独 を比較しています。 結果は、、 【2年無再発生存率】 82.2％ vs 70.0％ HR 0.58、p＜0.001 再発または死亡のリスクが42％低下。 【2年遠隔転移無生存率】 88.5％ vs 80.2％ HR 0.62、p＝0.002 遠隔転移または死亡のリスクが38％低下。 Grade 3〜5の治療関連有害事象は 14.2％ vs 13.4％でした。 全生存期間はまだ追跡が必要ですが、キイトルーダに上乗せして再発を減らしたというのは、臨床的には重要な結果だと思います。 ところが、、 モデルナの株価は、データ公開後に25％超下落したと報じられています。 「え、効いてるのに何で？」 ってなりますよね。 そもそもモデルナ株は、今回の治療への期待などから年初来500％超も上昇していました。 なので、良い結果が出ること自体は、すでに株価に織り込まれていたという話です。 加えて、先行する第Ⅱ相試験から期待されていたほどには 遠隔転移を抑える効果が大きくなかった、という受け止めもあったようです。 ただし、対象や追跡期間の違う試験をそのまま比較して「効果が落ちた」とは言えません。 個人的には、患者さんごとに作るmRNAがんワクチンが、第Ⅲ相で再発抑制効果を示したこと自体が大きいと思います。 ただ、これで色々ながんに効くと決まったわけではありません。 まずはメラノーマでの結果として評価して、OSと他のがん種の試験の結果を今後は見ていきたいですね。 ツチノコ的には数十年もすればゲノム含めがん治療は完全に個別化される可能性があると思っているので 標準治療の教育体系から変えていかなくてはならないのでは？ という印象です。 公式資料： https://t.co/NWcEXu7k0B⁠ #ESMO26 米モデルナの株価が一時26%安　治験データ漏洩、期待に届かず：日本経済新聞 https://t.co/ZM4mZ3zM9N

NATALEE at 6 years: Ribociclib + NSAI vs NSAI alone in HR+/HER2− early breast cancer: • 6-year OS: 91.86% vs 89.73% • OS HR 0.809 (95% CI 0.661–0.989); nominal 1-sided P=0.019 • Absolute OS benefit: 2.1% • 6-year iDFS: 83.23% vs 77.92% • iDFS HR 0.741 (95% CI 0.646–0.849) • Absolute iDFS benefit: 5.3% Is OS significant? Looking forward to full data .@Timothee_MD @myESMO @OncBrothers @OncoAlert #ESMO26 #BreastCancer #NATALEE

Congrats to the SARON investigators! Important randomized data for a question we face all the time. 👏 Consolidation RT improved local control and PFS, but no OS benefit demonstrated: HR 0.99 (95% CI 0.63-1.55). The RT details caught my eye. Of 62 pts who received RT, 51 had conventional treatment to the primary and only 11 had primary SABR. About 53% of the full cohort had N2/3 disease. Side note: in the separate 13-pt ESTRO safety substudy, the most common schedules were 55 Gy/20 fx to the primary (10/13 pts) and 27 Gy/3 fx to thoracic mets (4/14 lesions). Those are substudy doses, not the dose distribution for the whole trial. Curious how pts who actually received SABR to all sites did. That would be exploratory, but I'd like to see the dose/volume details and patterns of failure before generalizing these results to patients receiving total consolidation. Looking forward to the full paper! #ESMO26 #radonc https://t.co/3AtnSapEMk

GY020 didn't meet its primary endpoint: 3y success 70% w/ pembro+RT vs 73% RT alone. Leaving study counted as failure. KM RFS numerically favored pembro, but CI crossed 1. G3/4 toxicity 43% vs 15%. RT alone remains my default here. #ESMO26 #radonc https://t.co/tmjNMzulqN https://t.co/KR1rbuVzhW

Encouraging pancreas SBRT data from MASTERPLAN. Adding 40 Gy/5 fx cut 12mo locoregional recurrence from 52% to 20% (P=.022). OS 22 vs 14mo, but this is a 74-pt phase II with mixed resectability. Promising; not definitive OS evidence. #ESMO26 #radonc https://t.co/V1L9O30kcB https://t.co/mQ9DiXp7qH

14.8% invasive local recurrence at 5y after BCS alone in TOP-1. Age 70+, small low-grade ER+ tumors, no RT or ET. Most recurrences were salvaged, but that is still more treatment. I'd be cautious about routinely omitting both. #ESMO26 #radonc https://t.co/QD1spCSEAb

HR 0.58 is right where the phase 2b was, and they used a real pembro control, which I give them credit for. Unfortunately this is RFS on top of a pembro backbone that was itself approved on RFS. COMBI-AD showed big adjuvant RFS and DMFS gains with no significant OS difference. Patients who recur now have good salvage options, so treating earlier isn't necessarily curing more people. Fever in 52% vs 8% means nobody was really blinded. I'd want OS before calling this a new standard.

‼️ Interesting commentary on INTerpath-001 No need for vaccine if pembro given neoadjuvant? Wow, await further details / data here, but what a dud! Precision/Personalized dud https://t.co/i1SNiVUjfz

🚨SANO 5y: surveillance vs surgery after cCR OS 50% vs 54% (NS) Distant mets 46% vs 29% (P<.01) Reminder: only 41.4 Gy/23 fx, a pre-op, arguably non-definitive dose, especially with/ ~75% adenocarcinoma. Nonsignificant OS doesn't establish noninferiority. #ESMO26 #RadOnc #OncTwitter

This is nice! I'm excited to share all the great science, emerging questions and new therapies for our patients with gynecologic malignancies. Let's GO @myESMO 2026 https://t.co/56k9dpQYUe

🚨UNION Trial🚨 Locally advanced rectal cancer N=231 🔍Randomized 🔵Chemoradiation➡️2c CAPOX➡️TME➡️6c CAPOX 🟢SCRT➡️2c CAPOX + camrelizumab ➡️TME➡️6c CAPOX+ cam 🔥SCRT + chemo-IO demonstrated a whopping difference in EFS, 91% vs. 77%!!! #ESMO26 https://t.co/rQz7cbbpZx

PRABITAS phase III trial pragmatic trial enrolled 972 pts in 17M evaluating the schedule of TAS-102 + bev (2 weeks on/2 weeks off) vs. (1 week on/1 week off) which validates non-inferiority and less dose reductions validating our RWD approach in the US. #colorectal #cancer #ESMO2026 @OncoAlert

6. DUO-E (Updated OS): PhIII, Durva + chemo → Durva + olaparib vs chemo alone in advanced/recurrent endometrial cancer. - mOS 51.1 vs 39.6 mo (HR 0.77) - Interim analysis did not meet formal statistical threshold - Numerical benefit seen in pMMR 8/10 https://t.co/pgdlUuAvCy https://t.co/ququuaxl11

Day 2 #ESMO26 Highlights: 1. CheckMate8HW: Nivo+Ipi in mCRC Breast Ca 2. postMONARCH: Abema+Fulv HR+ 3. VIKTORIA-1: Gedatolisib HR+ 4. TROPION-Breast02: DatoDXd TNBC GU/Gyn 5. PROTEUS: Periop Apa+ADT in Prostate Cancer #OncTwitter #bcsm #gusm #gism @myESMO 1/10 https://t.co/OR4vj1ZJUM

Median OS almost 2 years in ES-SCLC with Tarlatamab+Durvalumab maintenance = practice changing! ➡️ Challenge remains implementing Tarlatamab broadly + equitably so that all patients with ES-SCLC may benefit from this revolutionary therapy. @OncoAlert #ESMO26 @NEJM https://t.co/Ug6TxnAd1J

TROPION-Breast02, brain mets subgroup at ESMO 2026. First-line Dato-DXd vs chemo in mTNBC, n=61. CNS PFS 9.5 vs 2.6 mo, HR 0.27. Intracranial ORR 62.5% vs 37.5%. Longest intracranial response about 27 mo. In TNBC, brain mets come early and we usually treat them locally first. This makes me ask whether a patient with small asymptomatic lesions could start Dato-DXd and defer /combine SRS Not ready for clinic. This is a post hoc subgroup, n=30 with untreated brain mets. And even on Dato-DXd, median OS was 11.6 mo with brain mets vs 23.7 mo without. The CNS benefit is real; the prognosis is still poor. The answer needs a dedicated CNS trial. #bcsm #ESMO26 @myESMO

Every year, @myESMO #ESMO26 is an opportunity for me to reflect on the huge amount of work that the #CommunicationCommittee is doing throughout the year Thank you for all your time, vision and knowledge What we do is relevant, and matters 😊 https://t.co/9aoyLMnuAH https://t.co/KlVLylA8Xx

In patients with HER2-positive advanced #breastcancer, the HER2-targeted bispecific antibody #anbenitamab plus albumin-bound docetaxel led to 24-month progression-free survival of 58.5%, as compared with 34.4% with standard therapy. #ESMO26 https://t.co/r3scKJw8Dc

In a prespecified interim analysis of a phase 3 trial involving patients with extensive-stage SCLC, the median overall survival was 21.1 months with #Tarlatamab maintenance therapy and 12.7 months with durvalumab alone. #ESMO26 https://t.co/xuqEkJZSSn https://t.co/FBAHoeWXyv

Lots of exciting developments at #ESMO26! Several important studies were also published simultaneously in major medical journals. A few highlights: 1. Small-cell lung cancer (NEJM): Adding tarlatamab to first-line durvalumab maintenance improved median overall survival from 12.7 to 21.1 months in the phase 3 DeLLphi-305 trial. 2. HER2-positive breast cancer (NEJM): Anbenitamab, a HER2-targeted bispecific antibody, plus HB1801 improved 24-month progression-free survival to 58.5% vs 34.4% with standard therapy (HR 0.46). 3. Muscle-invasive bladder cancer (NEJM): Perioperative durvalumab plus neoadjuvant enfortumab vedotin improved 24-month event-free survival to 63.5% vs 45.1% with surgery alone. 4. HR-positive, HER2-negative breast cancer (Lancet): The EGFR/HER3-targeted bispecific antibody-drug conjugate izalontamab brengitecan doubled median progression-free survival versus chemotherapy (8.2 vs 4.0 months; HR 0.41) in the phase 3 PANKU-Breast01 trial. 5. Melanoma (Nature Medicine): Five-year RELATIVITY-047 results showed sustained overall survival benefit with nivolumab + relatlimab vs nivolumab alone (HR 0.78). Full publications below 👇

This is simply amazing. @dr_yakupergun @myESMO How can questions and answers session for presidential symposium be cut off ? #ESMO26 https://t.co/KwVSbC35ea https://t.co/ERWhYNLosR

Honoured to join Prof. Domenica Lorusso this morning at the @myESMO Clinical Session Guidelines, presenting the new ESMO cervical cancer guidelines 🙌 #ESMO2026 https://t.co/1WMZuKpEBc https://t.co/vXFlJnWr6P

Day 2 (Presidential) #ESMO26 1. INTerpath001: mRNA vaccine in melanoma 2. VOLGA: Durva+EV in MIBC 3. DASLHiCaP: Dara+ADT+RT in Prost Ca 4. DeLLphi305: Tarla+Durva ES-SCLC #OncTwitter @myESMO #gusm #lcsm @OncoAlert @OncUpdates @DanaFarber @sands_jacob @tompowles1 1/5 https://t.co/Yu3s24fNTY https://t.co/yT1CxCZCYI

Who’s behind the ESMO Open (@ESMO_Open) social media handle? 👋 Ciao from Paolo & Paolo #PaoloBironzo https://t.co/bFYGViDRV0

Putting STAMPEDE, ENZARAD, PROTEUS & DASL into context with the latest #ESMO26 updates: STAMPEDE: Abiraterone-based intensification improved MFS AND OS, predominantly with RT. New #ESMO26 Decipher data suggests differential abi benefit in cN0 disease (interaction P=.01); using this to omit treatment still requires validation. ENZARAD: At 8 years, MFS was 74% vs 72% (HR 0.88; P=.34). No significant overall MFS benefit from enza + ADT/RT. The cN1/planned pelvic RT subgroup signals remain hypothesis-generating. DASL: new at #ESMO26: 1,106 patients; 96 weeks of daro v. placebo + ADT + prostate/bed AND pelvic RT. Four-year conventional-imaging MFS: 95% vs 88% (HR 0.42). Very-high-risk population, including selected postoperative patients. Interim analysis; OS immature. PROTEUS main trial: Perioperative apa + ADT improved 5-year PSMA-inclusive MFS versus ADT alone: 78.2% vs 73.5% (HR 0.80). Conventional-imaging MFS was not statistically significant. #ESMO26 post hoc PSA-response analysis adds prognostic information. PROTEUS randomized substudy: new at #ESMO26: Perioperative apa/ADT + RP/PLND (n=102) v. immediate RP/PLND (n=306). At 37.8 months’ follow-up: • 3-year EFS: 63.0% vs 41.4%; HR 0.38. • Secondary PSMA-inclusive MFS: HR 0.49; nominal P=.0193. • Subsequent postoperative RT: 20% vs 43%. The substudy strengthens a "perioperative strategy". But conventional-imaging entry followed by PSMA-inclusive endpoints matters. PSA-based EFS, conventional MFS and PSMA-inclusive MFS are different endpoints. These trials support specific intensification strategies; they cannot rank the drugs or establish RP-versus-RT superiority. The decision remains who benefits enough to justify the ENTIRE treatment burden.

The moment I saw the overall survival curves, I wanted to stand up and applaud! 👏 40,000 of us at #ESMO26, sharing the same excitement and hope not for ourselves, but for our patients. ❤️ A truly emotional moment in #SCLC. #DeLLphi305 @StephenVLiu @sands_jacob @lungoncdoc https://t.co/FxDFvv1EMP

🚨📣📣 #ESMO26 presidential: @niazi_Dr7 Adding darolutamide to ADT + RT dramatically ⬇️ risk of metastasis or death in high-risk localized prostate cancer. Phase 3 DASL-HiCaP = 58% ⬇️ in MFS (HR 0.42) + early OS signal (HR 0.88). #ProstateCancer #RadOnc #pcsm @ChrisSweens1 https://t.co/7JuxQ3qSr9

DeLLphi-305 a new standard of care in ES-SCLC Tarlatamab maintenance + Durvalumab after induction chemo-IO Huge win against SCLC! Congrats @sands_jacob and DeLLphi-305 group And a standing ovation! 👏🏼 https://t.co/a4380aJDuB

🚨 CheckMate 8HW | #ESMO26 Dual immunotherapy delivers an OS win in MSI-H/dMMR metastatic CRC! NIVO + IPI vs NIVO (all lines): ✅ 5-year OS: 74% vs 62% ✅ OS HR 0.61 (P=0.0009) ✅ ORR: 72% vs 58% 🔥 First significant OS benefit of dual IO over single-agent IO in this setting. @ESMO_open @my_esmo @ASCO @oncoalert

And the room rises! What a moment for the team and the patients at the heart of this work! 👏 #ESMO26 @oncoalert @myESMO @DanaFarber @sands_jacob https://t.co/cXdbJFY65L

Standing ovation al convegno della Società Europea di Oncologia Medica Presentazione dei risultati di una nuova terapia contro il cancro al polmone l’uditorio si alza in piedi e applaude a scena aperta. Tutti i dettagli prossimamente sul mio Substack. https://t.co/kIcWAybbFc

💥Game-changer in small cell #lungcancer! #ESMO26 LBA3 DeLLphi-305: Tarlatamab + durvalumab vs durvalumab 1L maintenance in ES-SCLC (n=563) after chemo-IO. Median OS ⬆️ 21.1 vs 12.7 mo (HR 0.42), PFS ⬆️7.4 vs 1.9 mo (HR 0.34), ORR 26% vs 4%. ☢️44% of pts still on T+D due to #radiotherapy of oligoprogressive sites? #SCLC #LCSM @NEJM ➡️ https://t.co/nhVH10CQZG

Starlatamab takes a huge BiTE today out of small cell lung cancer! Amazing PFS (0.34) and OS (0.42) HR and truly manageable added tox- 50% CRS but almost uniformly gr 1/2 and near non-existent ICANS, no new safety signal w durva combo just makes this one of the most impressive SCLC trials/ cancer trials ever.. Given extreme need for better treatments for our pts w ES-SCLC, unprecedented benefit seen in DeLLphi-305 plus availability/experience with use already it is a no-brainer to incorporate into our practice as SOC maintenance therapy on Monday… well, not Mon- whenever your flight takes you back post-#ESMO26 Amazing job by @sands_jacob and Amgen/DeLLphi team- glad we had a chance to offer such a transformational trial to our pts as well at Monte/Einstein! With these extraordinary results starlatamab is likely to continue to expand into 1st line/LS-SCLC settings and lets just dream on- if we as a field have taken such a tasty first BiTE, can hardly wait for the next one! Standing ovation- well deserved! #lcsm

DeLLphi-305. Immpresive curves . Additional Toxicity and cost in real world needs to be seen . Good for patients with extensive SCLC @myESMO @OncoAlert #esmo26 https://t.co/V2CDG9m0ZR

ctDNA analysis is an increasingly utilised prognostic tool in muscle invasive bladder cancer. In VOLGA 78% of the muscle invasive bladder cancer patients were ctDNA positive at baseline which was prognostic. Also, the combination of perioperative durvalumab and neoadjuvant EV cleared ctDNA in 60% of patients (using the Natera Genome assay which has increased sensitivity). Clearance was associated with much better outcomes. #ESMO26

🆙#ESMO26 Presidential Symposium I: #LCSM 🔥DeLLphi-305: Tarlatamab Plus Durvalumab (Durva) vs Durva as 1L Maintenance (1LM) Therapy Following Durva, Platinum, and Etoposide in Extensive-Stage Small Cell Lung Cancer (ES-SCLC): Primary Analysis of the Phase 3 Trial 🎙️ @sands_jacob 🔢LBA3 🎯Met Primary Endpoint: Significantly Improved OS 🎯mOS 21.1 vs 12.7m, HR 0.42 🎯mPFS 7.4 vs 1.9m, HR 0.34 🎯ORR 26.4% vs 4.1% 🎯CRS 49.6% (Mostly Low Grade), No Fatal Events ☑️NCT06211036 🔗 https://t.co/Lb6tzuMm0z @OncoAlert @Larvol @myESMO @IASLC

Presidential Symposium 1 #ESMO26 @esmo @oncoalert https://t.co/yiZUtLoJ9A

My first ESMO oral! 🇪🇸 Our study: immunotherapy around cancer surgery becomes standard of care before we know if patients live longer, mature survival data should come first. Grateful to my mentors and my family ❤️ #ESMO26 @oncology_bg @dr_rajapramanik @gupta_aarushi https://t.co/PykpnULhPi

VOLGA also explored short periods of EV with duvalumab and tremelimumab in muscle invasive bladder cancer #ESMO26 @NEJM. Results showed EVDT improved EFS vs cystectomy (HR 0.61). Significant OS was not reached at this interim (HR 0.77 -ongoing analysis). EVDT = 10% higher rates of G3/4 toxicity and less EV delivery than the EV durvalumab arm. More is not always better. It appears the addition of treme partly compromised delivery of EV, which likely accounts for the more modest results compared to the doublet @OncoAlert

Six phase III trials. Six different stories. Higher pCR does not guarantee better survival. In muscle-invasive bladder cancer, EFS and OS matter more than impressive response rates. Are we measuring what truly matters to patients? @myESMO @OncoAlert @OpenMedicineHQ #ESMO26 @tompowles1 @urologysummit @Uromigos @Uroweb @urotoday

VOLGA explored short periods of EV (3 cycles) with duvalumab in muscle invasive bladder cancer #ESMO26 @NEJM. Results showed EVD was associated with better EFS + OS vs cystectomy alone (0.51 and 0.58 respectively). pCR 40-45% with ctDNA clearance rates of 60%. High rates of adjuvant IO therapy uptake and low rates of neuropathy suggest potential advantages of this approach which focuses the ADC in the neoadjuvant phase. It’s likely to be attractive for patients.

I thought #ESMO26 was the year of IO and this CART just came out of nowhere to smash expectations 🤯
Is this real? SL-28 (1002O): off-the-shelf allogeneic leukocytes from healthy donors. No genetic modification, no HLA matching, no conditioning. 12 heavily pretreated patients. • ORR 66.7% (4 CR, 4 PR)
• 4 SD, 0 PD
• mDoR not reached in responders
• mPFS 24.7 mo 
• 4 of 12 patients died, all labeled non-cancer related. In a cell therapy dataset I need to know what killed them. 
• The 12 mix a Phase 1/2 that started in 2026 with expanded-access patients. A 24.7 mo median PFS likely utilizes the compassionate-use cases. 
• SL-28 runs on "TezR" receptors, a system first described by the company's founders (one of whom presented today). I'd love to see someone else replicate it. Have we finally entered the era of solid tumor CAR-Ts? @OncoAlert @TheGutOncLab @Onco_Nexus

👑 Presidential #ESMO26! INTerpath-001: personalized mRNA vaccination reaches phase III in melanoma. Resected stage IIB–IV melanoma, N=1,137: intismeran + pembrolizumab vs pembrolizumab. 💥 At 24 months: • RFS: 82.2% vs 70.0% → HR 0.58 • DMFS: 88.5% vs 80.2% → HR 0.62 • Absolute gains: +12.2% RFS / +8.3% DMFS • Benefit emerges mainly after 6 months • Grade ≥3 AEs: 23.6% vs 20.3% • OS still immature A clinically meaningful new mechanism, but the real question now is positioning 🤔 For macroscopic stage III: adjuvant personalized vaccine after surgery, or neoadjuvant ipi/nivo before it? Biomarkers may ultimately decide. Congrats to @ProfGLongMIA and all the team! 👏🏼 @OncoAlert @OncoReporte @myESMO @_SEOM @GrupoMelanoma

#ESMO26 Presidential 1 : #SCLC DeLLphi-305: Who would have imagined some years ago that median OS of SCLC would equal that of non-AGA NSCLC! #Tarlatamab as 1L maintenance with Durvalumab after induction chemoIO in ES-SCLC improved OS from 12.7 to an impressive 21.1m, corresponding to a HR of 0.42. 80% of patients alive and 38% progression-free at 12 months The dawn of a new era for thoracic oncology and for the lives of our patients 💫✨ @myESMO @SclcSMASHERS #ESMOAmbassadors

I admit i am very much into intismeran…and it seems many others too as it is standing room only here… Fabulous presentation/data on the Interpath-001 trial demonstrating clear benefit of this space age bespoke neoantigen vaccine along w pembro for pts w resected high risk melanoma as to 40% or so improvement in RFS/distant met free survival Indeed a landmark trial for precision medicine and hopefully not too Long before we see confirmation in nsclc/other trials! Interpath- indeed makes us foresee a wonderful path and light ahead for our field! #ESMO26

#ESMO26 INTerpath-001 8 Grade 5 AEs in the experimental arm, 0 in the control arm. Of course, it could all be pure coincidence! After all, 6 of the 8 events were not considered TRAE Perhaps it was just the excitement of being randomized to the experimental arm? I'm genuinely curious about the independent causality assessment.

#ESMO26 Starting the Presidential Session with INTerpath-001 Intismeran + pembro shows ⬇️risk of recurrence and of distant mets including high-risk stages. A major step forward for personalised cancer vaccines, looking forward to see the data in other tumour types @OncoAlert https://t.co/SBGq9djNGK

INTerpath-001 - the result of decades of scientific advances and research led to this moment! And brilliant delivery by @ProfGLongMIA Personalized mRNA vaccines + Pembro as adjuvant trt improve RFS for pts with resects IIB-IV Melanoma!! Important points: Tox: a significant number of adverse events occurred BEFORE the vaccine was started Access: the vaccines was given globally #ESMO26 @OncoAlert

#ESMO26 Interpath-01; 🚨addition of individual tumour directed mRNA vaccine intismeran n=1137 patient phIII trial in resected #melanoma to pembro anti-PD1. ⬇️ risk of distant mets or death by 38%. Similar G3-5 TRAEs similar ~14%. OS not mature. 💥A new era in personalised mRNA therapy?

Today I had the pleasure of presenting an #HCC case at #ESMO26 and taking part in a multidisciplinary discussion with an outstanding panel of experts! A great opportunity to exchange perspectives on the management of HCC. Many thanks to all the speakers and organizers! https://t.co/585uyrzMI3

Nice tribute to Jeff Weber at conclusion of InterPath1 @ProfGLongMIA #ESMO26 #melanoma https://t.co/pu4KKOi95d

🆙#ESMO26 Presidential Symposium I 🔥INTerpath-001: Phase 3 Study of the mRNA-Based Individualized Neoantigen Therapy (INT) Intismeran Autogene (Intismeran) Plus Pembrolizumab (Pembro) vs Pembro Alone for Adjuvant Treatment of Resected Stage IIB-IV Melanoma (MEL) 🎙️ @ProfGLongMIA 🔢LBA1 🎯Met Primary Endpoint: Significantly Improved RFS 🎯24-Mo 82.2% vs 70.0%, HR 0.58 🎯DMFS HR 0.62 🎯Grade≥3 AEs 23.6% vs 20.3% ☑️NCT05933577 🔗 https://t.co/Lb6tzuMm0z @OncoAlert @Larvol @myESMO

A milestone for personalized cancer vaccines. INTErpath-001: 42% lower recurrence/death risk; 24-month RFS 82.2% vs 70%. Can we extend this benefit to other cancers? @myESMO @OncoAlert @OpenMedicineHQ #ESMO26 https://t.co/567xy0e42L

#INTerpath001 amazing adjuvant melanoma trial of a personalized vaccine plus pembrolizumab. 17% of patients didn’t have sufficient tumor sample to create the neoantigen vaccine. DFS highly positive and OS immature. @oncoalert #ESMO26 excited to see other tumor data coming soon! https://t.co/VyUKabIWE2

Presidential symposium stage IIB-IVメラノーマに対する個別化ネオアンチゲンワクチン+ペムブロリズマブのアジュバント INTerpath-001試験。 RFSをHR 0.58で有意に改善。DMFSも改善。 これは一つの歴史の転換点だ。 NEJM同時掲載。 #ESMO26 https://t.co/Wy3KjpqZjt

Incredible cancer breakthrough #ESMO26 w/ new benchmark in melanoma & huge advances for all future personalized tx that could extend to other cancers 🌟 Ph3 Intismeran autogene mRNA vaccine improved RFS by 42% w/ Pembro vs Pembro alone, distant mets reduced by 38%, similar AEs https://t.co/VLSxKxCOWy

🔥 #ESMO26 INTerpath-001, full data (now yes) On top of RFS HR 0.58 and DMFS HR 0.62: • Manufacturing success >99% • >90% of patients got the maximum 34 neoantigens 🔍 Practice-changing? For a population, yes. Two things still to prove: • Can an mRNA strategy rescue patients primary refractory to neoadjuvant ipi-nivo (no pathologic response)? • Will it move OS in stage II-IIIB too? Resuls in @NEJM soon @myESMO @OncoAlert @Larvol @_SEOM #Melanoma #Immunotherapy

From #ESMO26 & @NEJM Tarlatamab–Durvalumab Maintenance for Extensive-Stage Small-Cell Lung Cancer https://t.co/locTy831XT Practice changing data for a terrible disease with hazard ratios that are unequivocal.

A long-awaited breakthrough in cancer vaccines. One patient. One tumor. One personalized mRNA vaccine. INTErpath-001 brings this vision closer to clinical reality. Are we ready to deliver it? @myESMO @OncoAlert @OpenMedicineHQ #ESMO26 @ProfGLongMIA @FAndreMD @curijoey @YJanjigianMD

#ESMO26 | INTerpath-001👇 https://t.co/9zQwLrfkBe https://t.co/jA8OFWtQqd

🔥 Personalized cancer vaccines delivering impressive results at #ESMO26! @ProfGLongMIA presents the phase III INTerpath-001 trial in resected high-risk melanoma. Individualized neoantigen mRNA vaccine intismeran autogene + pembrolizumab vs pembrolizumab alone. Key results: 🔹 DMFS: HR 0.62 (95% CI 0.45–0.85), p=0.002 🔹 24-month DMFS: 88.5% vs 80.2% 🔹 RFS: HR 0.58 (95% CI 0.45–0.75) A major milestone for personalized cancer vaccines! A promising step towards truly individualized immunotherapy. #ESMOAmbassador #ESMO26 #Melanoma #CancerVaccines #Immunotherapy

Superb presentation by Georgina Long! INTerpath-001: adding personalized mRNA vaccine intismeran to pembrolizumab reduced recurrence/death risk by 42% in resected stage IIB-IV melanoma (HR 0.58). A major step for cancer vaccines! #ESMO26 @OncoAlert @myESMO #ESMO26 https://t.co/9miRzK7fhb

🚨🔥@OncoAlert Hot off the press. Just published @NEJM in conjunction with presentation @myESMO #ESMO26 the long-awaited #PracticeChanging results of: ⭐️#DeLLphi305 phase 3 trial of: ❇️1st line maintenance #Tarlatamab + #Durvalumab) vs #Durvalumab alone in patients with #ExtensiveStage #SmallCell #LungCancer after initial induction Tx with #Chemo + Durvalumab. Study showed: ‼️#Impressive statistically significant & clinically meaningful ⬆️#OverallSurvival Benefit. ✅#mOS: 21.1 vs 12.7 months (HR 0.42) ✅12-month OS: 79.4% vs 53.3% ✅#mPFS: 7.4 vs 1.9 months (HR 0.34) ⚠️ Grade ≥3 #AEs: 46.8% vs 40.6% * In Tarlatamab arm: #CRS: 49.6% (Grade ≥3: 0.4%) #ICANS: 1.1% (Grade ≥3: 0%) 👇🏻 https://t.co/JoYBDSUAo9

#ESMO26 Presidential 1: As Tarlatamab moves from the 2L to the 1L setting, it suddenly becomes taller 😄😄 Congrats @sands_jacob , we are here to celebrate with you for the dawn of a new era for our patients with #SCLC @myESMO @SclcSMASHERS @StephenVLiu https://t.co/67gP35Kl82

The #ESMO26 Presidential Symposium is about to begin! 🔥 Super excited to hear the highly anticipated results of the VOLGA trial, presented by the the only and only @tompowles1! @myESMO @apolo_andrea @Uromigos @brian_rini @OncoAlert @LosUromigos @uromigosjapan @MichvdHeijden

Shout out to the PRABITAS study team 🇯🇵 for providing Level 1 evidence to confirm earlier RWE (with a pragmatic design and no industry funding!) ➡️ biweekly TAS102 should be the new standard for SUNLIGHT ➡️Simultaneous publication in @TheLancet https://t.co/o6Vor5Ms9a ➡️Great discussion by @KaiKeenShiu #ESMO26 @myESMO

🔥 Front row, great colleagues, and sky-high expectations! @AndrearicFili @MehrpouyaMobin @RobertoFerrara_ @DrJNaidoo @bensolomon1 Get ready for an UNFORGETTABLE Plenary Session at #ESMO26! 🚀 The excitement is real, the room is packed, and we are ready for what could be some truly practice-changing data in oncology! Let the science speak! 🔬💥 #ESMOAmbassador #ESMO2026 #ESMO26 #Oncology #CancerResearch #PracticeChanging

2/ GY020 was powered for 80%→95% 3-yr RFS. That’s a 75% reduction in failures, roughly HR 0.23, for single-agent IO added to RT in early-stage disease where VBT already controls most disease. A big ask for 168 pts. (figure made with claude ai) https://t.co/n2n1Rc5hv5

@myESMO @FBackesMD 1/ NRG-GY020 at #ESMO26: RT ± 1 yr pembro in stage I/II high-intermediate risk dMMR endometrioid EC (n=168, 1:2). The primary endpoint, 3-yr recurrence-free status, was negative: 73% vs 77%, p=0.31. Question - is this really negative or is this a case of over aggressive statistical design to conserve sample size? 🧵

🔥 Thank you for highlighting our study, Prof. @ArndtVogel! 👏Truly excited about the potential of BGB-B2033 (#GPC3 x 4-1BB) in advanced #HCC and looking forward to the next steps. @myESMO #ESMO26 #ESMOAmbassadors https://t.co/BrbK2phy6T https://t.co/z6rsLCqLaY

#ESMO26 PROTEUS discussion by Nicholas van As • No baseline PSMA PET; enrolled conventionally staged M0 • MFS events: true progression or delayed detection? Most were PSMA PET-detected (8.8% vs 16.3%) • TTST HR 0.29, but ~20-mo lead-time bias #ProstateCancer https://t.co/FfugtpcYwU

Final OS results from CheckMate 8HW: Nivo plus ipi vs nivo or CTx in MSI-H/dMMR mCRC #ESMO26 #ESMOAmbassadors 👉ORR 72% 58% 👉mOS: NR --> NI vs N HR 0.66 👉5-yr for Nivo/Ipi: 77% 🧐Convincing, Nivo + Ipi as SOC in 1L MSI CRC @myESMO @ASCO https://t.co/ni6wO1FZAW

#ESMO26 🧬 PRABITAS | Phase III 👥 970 pts | Refractory mCRC 💊 FTD/TPI + BEV: biweekly vs conventional ⏳ mOS: 11.3 vs 10.3 mo ✅ Non-inferior OS (HR 0.93; p<0.0001) 📈 mPFS: 3.9 vs 3.9 mo ⚠️ G≥3 neutropenia: 13% vs 39% 💉 G-CSF use: 3% vs 13% 🚀 Similar efficacy, less toxicity! @OncoAlert

Biweekly vs conventional trifluridine/tipiracil plus bevacizumab for refractory mCRC: The pragmatic ph 3 PRABITAS trial #ESMO26 #ESMOAmbassadors 👉ORR: 2 vs 2% 👉 mPFS: 3.9 vs 3.9 mo 👉 mOS: 10.3 vs 11.3 mo 🧐similar efficacy, less toxicity, supports biweekly schedule @myESMO @ASCO

#ESMO26 🧬 Epsametostat (HH2853) | Phase II 🎯 Advanced epithelioid sarcoma 💊 Dual EZH1/2 inhibitor 👥 94 pts | 75 efficacy-evaluable 📈 ORR: 40% | DCR: 77.3% ⏳ mPFS: 13.1 mo | mDoR: 15.6 mo 🎯 mOS: Not reached ⚠️ G≥3 TRAEs: 39.4% 🚀 Primary endpoint met! https://t.co/ya44WOgSgG

Among the big news from #ESMO2026: PROTEUS companion RCT (not a substudy ¯\_(ツ)_/¯ ) comparing neoadj apa/ADT to RP alone. Impressive early results, should put to rest at least some of the objections to PROTEUS main paper. https://t.co/DTnUeyXi2D

Two #ovariancancer ADC readouts at ESMO 2026, and together they challenge how we select patients. #BEHOLD_1 mocertatug rezetecan (B7-H4, TOPO1 payload), platinum-resistant ovarian: confirmed ORR 62% at 5.8 mg/kg, median DoR 12.2 mo. Responses at every B7-H4 level. Response tracked with cathepsin B, the enzyme that cleaves the linker, and with TOP1, the payload's target. Torvutatug samrotecan (FRα, TOPO1 payload): ORR 48% in FRα ultralow/null, 57% low, 62% high, with overlapping CIs. ctDNA complete molecular response 47%, no clean link to FRα. What I make of it:
With mirvetuximab, a DM4 payload, FRα-high was the gate. With TOPO1 payloads, the gate is falling. Nearly half of FRα-null tumors respond.
The biology that predicts response sits in the payload path: release and sensitivity, not antigen density.
That changes three things. Who we test: target IHC may exclude patients who would respond. How we sequence: after one TOPO1 ADC, the question is payload resistance, not a new target. How we design trials: stratify by payload biology, not by the antigen on the label. Exploratory and single arm. But the direction is consistent, and it is where the field should look next. #gyncsm #ESMO26 @myESMO

#ESMO26 | INTerpath-001: My Personal Perspective Ahead of the Presidential Session This innovation deserves recognition: a groundbreaking result for personalized cancer vaccines. However, in patients with macroscopic stage III melanoma who are eligible for neoadjuvant IO, this trial does not establish the added value over contemporary perioperative strategies. Neoadjuvant treatment can produce substantial responses while allowing some patients to avoid adjuvant therapy. The trial design I would prioritize is: Neoadjuvant IO → surgery → standard adjuvant therapy ± a personalized vaccine in patients without a major pathological response. Here, “failure to achieve a major pathological response” is a more appropriate selection criterion than “any residual disease.” Patients with minimal residual viable tumor who still achieve a major pathological response should not automatically receive additional treatment. This approach would direct treatment intensification toward patients at higher risk of recurrence. The key biological uncertainty, however, is that IO-resistant residual disease is not necessarily vaccine-sensitive. Whether vaccination can overcome that resistance needs to be demonstrated. This criticism should remain specific to that population: INTerpath-001 retains distinct clinical value for patients with stage IIB/IIC disease and those who underwent surgery without neoadjuvant therapy.

Nice discussion by Dr Vicky Makker on DUO -E 🙂👍 @myESMO @OncoAlert @OncBrothers #ESMO2026 https://t.co/jGMKRTK9IR

NICHE-2. Keeping it short because the plot speaks for itself. 1. Rename it Chalabi's disease 2. Stop operating on patients first For those who don't know: 111 patients with locally advanced dMMR colon cancer got one dose of ipi and two of nivo, then surgery. Zero events. A flat line. Next up? Avoid the surgery altogether. #ESMO2026 @Onco_Nexus @OncoAlert @TheGutOncLab

DUO-E #ESMO26 Overall Survival Signals and the Added Value of PARP Inhibition in Advanced Endometrial Cancer @OncoAlert #ESMOAmbassadors #ESMOcommunity @myESMO https://t.co/vfsuUFj0wf

Conclusion in One line . Trial is negative for OS . And this approach should be used only in dMMR pts . #DUO-E @myESMO #esmo26 @OncBrothers @OncoAlert https://t.co/EpRGmXsAtS

#ESMO26 stage 1 TNBC @lab_kok presentation👇 https://t.co/gMMZbASQzb https://t.co/apEayvKx6h

I hate watching experimental therapeutics sessions where they say their drug is active in a wide range of “solid tumors” yet breast was excluded. We need new drugs too! Especially in #TNBC and Luminal B #BreastCancer . Please give us some non-TOPO-1 ADCs!!! #ESMO26

TRIDENTE: A phase II study of rechallenge with ENCO, BINI, and CET in BRAF V600E-mutant mCRC #ESMO26 #ESMOAmbassadors 👉mPFS: 2.8 mo 👉mOS: 9.6 mo 👉ORR: 19% 🧐Supports biomarker-driven re-challenging concepts for 🎯therapies in CRC @myESMO @ASCO https://t.co/OEuTM83GGe

#ESMO26 Current Guidelines for Stage I Triple-Negative Breast Cancer From @lab_kok excellent presentation👇 https://t.co/Yk4uuzxvkA

Encorafenib plus cetuximab beyond progression in combination with FOLFIRI in BRAF V600E mCRC progressing on EC: Results from the ECLYPse phase II trial #ESMO26 #ESMOAmbassadors 👉 mPFS: 7.1 👉 mOS: NR 👉ORR 15% 🧐Interesting signal to continue EC, more translational data would be great @myESMO @ASCO

Our superstar postdoc @marc_eid presenting a novel liquid biospy approach for pancreatic cancer subtyping #MattFreedman @SylvanBacaLab @KarlSemaan Stay tuned for more ! #ESMO26 @myESMO @OncoAlert https://t.co/1xWynloZcM

At #ESMO26: Our real-world study of inavolisib in breast cancer found early survival consistent with INAVO120. Frequent AEs, treatment modifications, and acute healthcare use highlight the need for close monitoring and proactive toxicity management.@maryam_lustberg @ncasasanta https://t.co/gk5X28kvjU

WOW! BIG news for our patients with extensive-stage small cell lung cancer! Phase 3 DeLLphi-305 trial, adding tarlatamab to durvalumab maintenance after initial chemoIO: ✅ OS: 21.1 vs 12.7 months (HR 0.42) ✅ PFS: 7.4 vs 1.9 months (HR 0.34) Practice-changed! #ESMO26 https://t.co/t23SBNzfUD

DESTINY-Breast Guide: 1795TiP at #ESMO26 🌍 In triple-positive mBC, can we do DB-09 induction and PATINA maintenance? DB-09 made T-DXd + pertuzumab a 1L option. PATINA showed palbociclib + ET + HP maintenance improves PFS after induction (HR 0.75). DB-Guide puts them together. How long to induce? In a DB-09 post hoc analysis, median time to maximal tumor reduction was ~11 mo (~16 cycles) overall and ~13 mo (~19 cycles) in HER2+/HR+ disease. A 6-cycle stop (~4 mo) lands well before most patients hit their best response. DESTINY-Breast Guide (N=200, single-arm):
1️⃣ T-DXd + pertuzumab for 18-24 cycles (12m), or switch after 8 cycles with confirmed CR
2️⃣ Palbociclib + ET + HP maintenance
3️⃣ T-DXd retreatment at progression. Primary endpoint: 24-mo PFS. QOL built in. Recruiting in the US, Canada, Europe, China, Korea, and Australia, and coming soon to @UMGCCC #BCSM #HER2 #ADC #BreastCancer

Updated financial take on Merck vaccine data in the @WSJ Link to article is free https://t.co/lqmFEU9wch https://t.co/mqt5kxFV59

Great News! “Preclinical data demonstrate tumor response with AVA6103 in the setting of Enhertu resistance. Potential for prolonged responses with increased FAP+ fibroblasts recruited to the tumor during treatment with AVA6103.” #AVCT #ESMO26 https://t.co/VjPBdJxfYX

6/The ctDNA data deserve a flag: 47% complete molecular response, 87% any molecular response, with no clean relationship to FRα level. https://t.co/IZIeeOHbyL

So many highly active topo1 ADCs. The emerging biomarker work will help us better plan when to use these agents, whether the target matters, how to sequence and selection may be based on schedule and toxicity profiles. We are so close to prioritizing efficacy AND tolerability - wow.

5/ Torvutatug samrotecan (FRα/topo1) ORR 48.1% in FRα ultralow/null, 57.1% low, 61.7% high. A gradient, yes. But the confidence intervals overlap , and nearly half of FRα-null tumors responded. So do we need a biomarker at all here? https://t.co/m2mYihxMDD

4/ In the MoRez trial, 96% of the tumors were B7-H4 + and responses occurred at every expression level. Correlative work suggests Cathepsin B, TOP1 expression and matrix remodeling all associated with response. https://t.co/cwJWw8ydje

3/ The dose story is the toxicity story. From 4.8 to 5.8 mg/kg: Grade ≥3 neutropenia 24% → 60% Any-grade neutropenia 49% → 87% ILD or pneumonitis 7% overall, 8/9 grade 1-2 Primary G-CSF is now recommended across the program. https://t.co/6VZ829L7jz

2/ Mocertatug rezetecan (MoRez) (B7-H4, TOP1i payload), BEHOLD-1, 136 patients with PROC. Confirmed ORR 36% → 57% → 62% across 2.8, 4.8 and 5.8 mg/kg. Median DoR 12.2 months at 5.8 mg/kg, with 90% still in response at 6 months.(Claudeai used to summarize) https://t.co/tqx0Ob0dJQ

1/ ESMO 2026: updates on two ADCs in PROC, and (finally!) some biomarker data on why they work. References (Meric-Bernstam ESMO 2026; Lheureux ESMO 2026; Salutari ESMO 2026) 🧵

Breast oncologists searching for breast cancer trials in the #ESMO26 Presidential Sessions 🔍👀😅 https://t.co/sxbCUR4968

Figure 2/2: Not only myeloma! The same Saturday session includes new approaches in B-cell lymphoma, transformed DLBCL and R/R MDS/AML. Interesting early-phase signals—but novel mechanism ≠ new standard. Spanish wine, however, needs no Phase III trial. 🍷😆 #ESMO26 #HemeTwitter #Lymphoma #AML #MDS

Finally arrived in Madrid and hoping to make it to #ESMO26- but running into some unexpected obstacles @Tony_Calles https://t.co/MAc9DSbcJh

#ESMO26 Day 1 highlight for me: MASTERPLAN, now in Lancet Oncology. Radiation and pancreatic cancer have a complicated history. ESPAC-1 suggested adjuvant chemoradiation hurt. LAP07 and CONKO-007 couldn't show an OS benefit after chemo. A021501 closed its RT arm for futility. PREOPANC-2 was a draw. We walked through the adjuvant side of this story in Sem Rad Onc last year: https://t.co/qGkMfyjghA So why is MASTERPLAN different? Phase 2, 14 sites in Australia and NZ (can i just say I love the Aus-NZ studies). 74 patients with high-risk localized PDAC, randomized 2:1 to chemo ± SBRT 40 Gy/5 after induction. 12-mo locoregional recurrence 20.2% vs 52.0%, sHR 0.44, p=0.022 
PFS 11.9 vs 6.3 mo, HR 0.44 
OS 22.0 vs 14.0 mo, HR 0.45 
Grade ≥3 AEs 70% vs 64%. Why did this one work when others didn't? The rad oncs can explain the physics better than I can. I just read it as better tumor zap zap. Does it change practice? Maybe. I think we need to have a deeper conversation at every tumor board, but the juice seems worth the squeeze. @OncoAlert @TheGutOncLab @Onco_Nexus https://t.co/rt0c35UkcW

PROTEUS Substudy: Periop Apa + ADT with RP+PLND vs RP+PLND in HR PCa @urotoday #ESMO26 Periop APA + ADT (+ RP+PLND; n= 102) vs RP+PLND alone (n=306) 🚨EFS: HR 0.38, 95% CI 0.26–0.55 🚨MFS: HR 0.49, 95% CI 0.26–0.90 🚨TT 1st Sub Rx: HR 0.29, 95% CI 0.20–0.43 🚨All Gr Hot Flush: 64% vs 0.7%

Promising data presented by @AndreaNecchi at #ESMO26 #GDFather-NEO. Nivo + Visugromab • Higher response (pCR and ORR) • At median F/U 15.7 mo: no recurrence observed after pCR • No new safety signal Paper out in @NatureMedicine. Congrats Andrea and co-authors ! @myESMO @OncoAlert

#ESMO26 A subgroup analysis of the phase III POTOMAC trial in papillary-only high-risk NMIBC: 📌Papillary-only: DFS HR 0.56; 48-month DFS 84% vs 74% 📌T1 subgroup: DFS HR 0.48; 48-month DFS 85% vs 73% 📌High-risk recurrence: 13% vs 20% in papillary-only disease 📌 Fewer early high-risk events, BCG-unresponsive recurrences and cystectomies 📌The trade-off: Grade 3–4 AEs were 34% vs 16%. @UroToday @myESMO

SAC-TMT + pembro shows 68% response rates in metastastic bladder cancer #ESMO2026 . Trofuse-55 explores this combination in bladder sparing approaches in a randomized phase 3. The triplet with EVP seems a justified research randomised question. Triplet data from yesterday showed 81% RRs. @OncoAlert

Phase I study of BGB-B2033 (GPC3 x 4-1BB bispecific AB): Dose optimization and escalation update in advanced HCC #ESMO26 #ESMOAmbassadors 👉ORR: 30% 👉manageable safety 🧐very promising agent, looking forward to see combination with ICI @myESMO @ASCO https://t.co/BfjGLR3JMM

Phase III postMONARCH: Final OS Analysis #ESMO26 @KalinskyKevin Abemaciclib + fulvestrant numerically improved OS after CDK4/6i (32.1 vs 24.6 months; HR 0.80, P=0.11), without statistical significance. PFS (HR 0.78), PFS2 (HR 0.76), and time to chemotherapy (HR 0.76) favored abemaciclib.

#ESMO26 | postMONARCH – Final OS After progression on CDK4/6i + ET, median OS with abemaciclib + fulvestrant was 32.1 vs 24.6 months, but statistical significance was not reached (HR 0.80; 95% CI 0.60–1.06; p=0.11). The 7.5-month difference in median OS is noteworthy, but these results do not make this combination a preferred second-line option for me, given the availability of biomarker-directed therapies.

#ESMO26 | Anbenitamab + HB1801 Am I reading this correctly? 55% of patients were HR-positive, yet none received endocrine therapy during the trial! This trial started in 2023, and the comparator was THP. Given the established role of endocrine therapy in HR+/HER2+ metastatic breast cancer, particularly during maintenance, how can we interpret these results without accounting for its omission? This raises serious concerns about the trial design and the applicability of its findings to contemporary clinical practice.

Great session on the multidisciplinary management of uterine #sarcoma #ESMO26 Unfortunately, the “typical” presentation of a case is still an unexpected diagnosis after histerectomy for presumed fibroids. Key take-home: refer patients early (pre-op ideally) for a center with experience in both sarcoma and Gyn malignancies; avoid morcellation at all cost; discuss with MTB since level of evidence across the care continuum is very low. @ctosociety @myESMO

JNJ-6143, first-in-class oral AR-BRD4 RIPTAC, phase 1 mCRPC: a wide window between efficacy and safety. n=105, doses 12.5 to 150 mg. 📈 50 mg daily: PSA50 77%, PSA90 48%, confirmed ORR 69%, after a median 4 prior lines 📊 PSA declines seen from 12.5 to 150 mg. 66% of all patients still on drug 🔍 At 50 mg: 58% any-grade TRAEs, no serious TRAEs. Median DOR 11.0 months, CI 5.9 to NE Activity across a 12-fold dose range. Phase 2 is open at 50 mg. Congrats to @BGarmezy on the presentation and all the investigators. #ESMO26 #ProstateCancer #mCRPC #GUonc

Much anticipated ACTICCA-1 ➡️adj cis/gem v cape #BTC ➡️mod ITT n=591 ➡️no diff in DFS at 24mth 52% v 44% RMST at 3 yrs ⬆️DFS by 2.6mth ➡️28% iCCA -no maj subgroup diff ➡️mOS 58.1 v 48.2 p=0.1 ❎No change to std ?an option, NB need as backbone 1st line! @myESMO @OncoAlert #ESMO26 https://t.co/zvbwqujcD1

A randomized trial of paclitaxel ± tovecimig in previously treated patients with advanced biliary tract cancer #ESMO26 #ESMOAmbassadors 👉 ORR: 18 vs 5.3% 👉 mPFS: 4.7 vs 2.6 mo 👉 mOS: 8.9 vs 9.4 mo 🧐Active drug, but no OS benefit in 2nd line, could be explored in 1L @myESMO @ASCO

Thrilled to share updated results from JNJ-6143, the AR-BRD4 RIPTAC therapy, presented by @BGarmezy. Totally novel MOA was well tolerated, oral pill and produced significant benefit for pts (PSA90 50%, ORR 68%). P2 trial active now and more coming. Lots of potential! https://t.co/spwrXBg5ZZ

ACTICCA-1 trial: Adj. GemCis vs standard of care after curative intent resection of BTC #ESMO26 #ESMOAmbassadors 👉 DFS at 2yrs: 52 vs 44% 👉mDFS: 23.3 vs 20.6 👉 mOS: 58 vs 48 mo 👉expected toxicity for the doublet 🧐 Trend for OS benefit, not an option for all, but may be considered as option for selected pts @myESMO @ASCO

evERA BC (Exploratory Analysis) #ESMO26 @stolaney1 Giredestrant + everolimus improved PFS vs standard ET + everolimus in HR+/HER2− advanced breast cancer (HR 0.56; ESR1m: HR 0.38). Benefit was generally consistent across ESR1 variants, clonality, and poor-prognosis genomic subgroups.

Fantastic presentation by Karim Fizazi! PEACE-1 at 7.7 years: adding abiraterone to ADT + docetaxel improved median OS to 6.2 vs 4.4 years (HR 0.68) in de novo mCSPC. Durable benefit from upfront intensification! @myESMO #ESMO26 @oncoalert https://t.co/C6GdCHh36O

ESMO 2026 Key late Breaking Abstracts Atypical EGFR mutation Enozertinib: Birth of Redwood 1 (2027) HERIZON-GEA-01 Her2+ GE Adenocarcinoma Zoci: ES SCLC https://t.co/Jj2g51gR06

Great start to the day at #ESMO26 seeing so many of our brilliant friends! @NarjustFlorezMD @MartinReck2 @AnaVManana @JustinGainor @isla_dolores #ESMOAmbassadors https://t.co/gCd1ffoakt

Nice discussion by Dr Rita Nanda . Clear message .🙂👍@esmo #ESMO2026 https://t.co/uyXCvGi49z

🔥 TODAY COULD BE ONE OF THE DEFINING MOMENTS OF #ESMO26! 🔥 The ESMO Presidential Symposium is always one of the highlights of the congress, and today’s session promises some truly extraordinary science! If I had to pick ONE study with the greatest potential to change clinical practice at ESMO 2026, my choice would be DeLLphi-305. For decades, SCLC has been one of the most challenging diseases in oncology, with far too little progress and far too few therapeutic breakthroughs. Could DeLLphi-305 finally represent the major leap forward we have been waiting for? We already know that adding tarlatamab to durvalumab as first-line maintenance significantly improves OS compared with durvalumab alone. But today, we will finally see the numbers. And I am genuinely excited to discover just how transformative this benefit might be! My personal bet for the biggest breakthrough of #ESMO26? DeLLphi-305. @StephenVLiu @sands_jacob Of course, the magnitude of survival benefit, safety and clinical applicability will ultimately determine its impact. But the potential is enormous. Don’t miss today’s Presidential Symposium! Madrid | 🕟 16:30 CEST Alicante auditorium #ESMO26 #ESMOAmbassador #SCLC #LungCancer #Immunotherapy #Oncology #PracticeChanging

TROPION-Breast02 brain mets analysis at #ESMO26 (Dent). 1L Dato-DXd vs chemo, mTNBC, n=61 with BMs: CNS PFS 9.5 vs 2.6 mo, HR 0.27 
icORR (measurable) 62.5% vs 37.5% 
Untreated BMs: OS HR 0.35
Longest icDoR ~27 mo Preferred Trop2 ADC for brain Mets! @RebeccaDSing Exploratory, small n, real CNS signal. #bcsm

#ESMO2026 @RitaNandaMD beautiful and balanced discussion of 2nd set of BC abstracts today. Highlighting her summaries below. https://t.co/6iNHA2UmqS

Very promising randomized results with the CDK4 selective inhibitor atirmociclib presented by @antgiorda. Next gen CDKs are here! #ESMO26 #ESMOAmbassadors https://t.co/XuIiabKA5H https://t.co/YuDTbHahRg

Promising activity between 53 and 80% of R-Dxd plus Bev in heavily pretreated PROC patients!! Nevertheless numbers are low and therefore this results are still preliminary but ver promising data! Congrats Dr Oaknin!! @OakninAna @myESMO #ESMO2026 https://t.co/vtNFH0OfSw

Iam shocked with the amount of excellent presentations and data in this session of #ESMO2026 now R-Dxd + bev with the results of the Rejoice2 trial. Presente by Dr Oaknin @OakninAna https://t.co/aD8srMQXTP

#ESMO26 Great start of Day 2 @myESMO with the #OncoAlertRun #Madrid26 Great organization by @weoncologists @OncoAlert It was 8°C but we made it 🔥👏🏽 👇🏽👇🏽 https://t.co/XO7qhALX7y

We move now to PSOC and the data of Sofe-M a FRalpha with an outstanding 79.3% Orr with Sofi-M plus bev!!! And almost 77% ORR in patients progressing while or on 6 months on PARPi !! #ESMO2026 https://t.co/FxTKLkrCMM

Nice translational analysis of the BEHOLD1. Happy to see that translational studies are also oral communications in #ESMO2026. Fantastic work by Dr Lhereux @StephanieLheur5 https://t.co/UYT8axYJxq

Peter Fasching summarizes the topics in HR+ disease from the first 3 talks in proffered session 2 @myesmo @OncoAlert #ESMO2026 https://t.co/6W2UUCWoWf

With VOLGA results coming at #ESMO26, a summary of contemporary phase III perioperative trials in muscle-invasive bladder cancer. ⚠️ Different populations and designs—avoid cross-trial comparisons. VOLGA and EV-303 importantly include surgery-alone control arms without neoadjuvant therapy. 🔑 The next challenge: identifying who truly needs adjuvant ADC therapy—and who can safely avoid it. #BladderCancer #GUOnc @OncoAlert @BladderCancerUS

今回の注目試験の一つ、PD-L1(CPS>1) HR+/HER2ーの化学療法へのペムブロ上乗せをみたKEYNOTE-B49。 PFSは有意に延長(HR 0.74)。ただ、6.7M vs 6.0と臨床的に有意とは言い難い。 CPS>10では良さそうな傾向。OSは延長なし。Practice changningとはいかないか... Ann Oncolに同時掲載。 #ESMO26 https://t.co/DYwLbq4CMO

KEYNOTE B-49: Chemo +/- pembro in PDL1+ (CPS≥1) HR+ MBC 79% CPS 1-9 53% recv'd capecitabine PFS: 6.7 vs 6.0 mo HR 0.74 OS: HR 1.04 PFS CPS≥10 :7.5 vs 4.4 HR 0.59 @OncoAlert @hoperugo #ESMO26 https://t.co/ZyCmtddjJq

🔴 Avrupa Onkoloji Kongresi (ESMO 2026)’nde açıklandı! Malign melanomda immünoterapiye, kişiye özel hazırlanmış mRNA kanser aşısının eklenmesi kanserin tekrarlaması veya ölüm riskini %42 azaldı Uzak metastaz riskini de %38 azaldı. Faz 3 INTerpath-001 çalışması. #cancer #oncology #ESMO2026

🚀Day 2 #ESMO26 Upper GI oral abstracts, summary results 🟢Paclitaxel + tovecimig ( vs paclitaxel) in 2L of advanced BTC improved ORR and PFS 🟢Adjuvant GemCis vs capecitabine in BTC, DFS median 2.14 vs. 1.49 years, log-rank p=0.097 🟣STRIDE ± L + TACE (EMERALD-3), stable liver function over treatment period and comparable safety regardless of baseline liver function 🟣BGB-B2033 (GPC3 x 4-1BB bispecific antibody) monotherapy in advanced HCC (phase I): promising ORR, further development #cancer #oncology #MedX #GI #gastrointestinal #biliary #liver #hcc #cholangiocarcinoma @OncoAlert

JUST IN: DeLLphi-305: Small Cell Lung Cancer Extensive-Stage Phase III (n=563): Tarlatamab + Durvalumab vs Durvalumab as 1L maintenance after chemo-IO, to be presented by our own @sands_jacob from @DanaFarber • Median OS: 21.1 vs 12.7 months (HR 0.42) • Median PFS: 7.4 vs 1.9 months (HR 0.34) • ORR: 26.4% vs 4.1% Grade ≥3 AEs: 46.8% vs 40.6%; CRS 49.6% (most low grade). Probably new standard of care in ES-SCLC. @OncoAlert @DanaFarberNews #ESMO26

🆙#ESMO26 Presidential Symposium I: #LCSM 🔥DeLLphi-305: Tarlatamab Plus Durvalumab (Durva) vs Durva as 1L Maintenance (1LM) Therapy Following Durva, Platinum, and Etoposide in Extensive-Stage Small Cell Lung Cancer (ES-SCLC): Primary Analysis of the Phase 3 Trial 🎙️ @sands_jacob 🔢LBA3 🎯Met Primary Endpoint: Significantly Improved OS 🎯mOS 21.1 vs 12.7m, HR 0.42 🎯mPFS 7.4 vs 1.9m, HR 0.34 🎯ORR 26.4% vs 4.1% 🎯CRS 49.6% (Mostly Low Grade), No Fatal Events ☑️NCT06211036 🔗 https://t.co/Lb6tzuMm0z @OncoAlert @Larvol @myESMO @IASLC

🆙#ESMO26 Presidential Symposium I 🔥INTerpath-001: Phase 3 Study of the mRNA-Based Individualized Neoantigen Therapy (INT) Intismeran Autogene (Intismeran) Plus Pembrolizumab (Pembro) vs Pembro Alone for Adjuvant Treatment of Resected Stage IIB-IV Melanoma (MEL) 🎙️ @ProfGLongMIA 🔢LBA1 🎯Met Primary Endpoint: Significantly Improved RFS 🎯24-Mo 82.2% vs 70.0%, HR 0.58 🎯DMFS HR 0.62 🎯Grade≥3 AEs 23.6% vs 20.3% ☑️NCT05933577 🔗 https://t.co/Lb6tzuMm0z @OncoAlert @Larvol @myESMO

DeLLphi-305 - tarlatamab added to durvalumab after initial chemo-immunotherapy for small lung cancer essentially doubles survival. Hope for all cancers here, if the right target & treatment modality can be refined. Unquestionably a new standard for this disease. #ESMO2026 https://t.co/8ovQ2yB6fr

Data from #ACTICCA1 (LBA) available - long time awaited #Adjuvant in #BiliaryMalignancies CisGem vs Capecitabine 🤔DFS HR 0.82, 95%CI 0.67-1.01 🤔DFS RMST first 3y p=0.01 🤔OS p=0.076 👀Full presentation 24/10/2026 10:25am 📝See you there @myESMO #ESMO26 #ESMOAmbassadors https://t.co/R86l6FaHNI

IO + EV upfront is now the SoC for MIBC!! But how much EV do we need in postOP settings? Eagerly looking forward to more data/discussion on Day 2 #ESMO26! VOLGA as the new SoC!!??!! #gusm @myESMO #BladderCancer https://t.co/vuu0mlgkY7 https://t.co/TQSEm2YESX

#ESMO26 DeLLphi-305: tarlatamab+durva vs durva, 1L maintenance ES-SCLC ➡️ OS 21.1 vs 12.7 mo, HR 0.42 ➡️ PFS 7.4 vs 1.9 mo, HR 0.34 ➡️ CRS 49.6% (G3+ 0.4%) Amazing to be part of this practice-changing study on the global steering committee!! @LungCancerRx @OncoAlert @oncodaily https://t.co/BfjokrDpim

💔 EV has a new partner! PEMBRO: “Another checkpoint inhibitor?!” 😳 EV: “We have survival data TOO!” ❤️ 🔥 VOLGA | ESMO 2026 EFS HR 0.51 | OS HR 0.58 But PEMBRO isn't out of the picture! KEYNOTE-905: EFS HR 0.40 | OS HR 0.50 Two promising perioperative partnerships in cisplatin-ineligible MIBC. ⚠️ Different trials. No head-to-head comparison. @myESMO @OncoAlert #MVOnco #ESMO2026 #BladderCancer

Improved MFS w/ darolutamide in DASL-HiCaP! 📌 1,106 very high-risk prostate cancer pts, incl persistent/rising PSA after RP. Randomised to darolutamide vs placebo w/ ADT + RT. 📌 Median age 71; GS 9-10 73%; CT N+ 29%; prior RP 15%. 📌 4y MFS on conventional imaging: 95% vs 88%, HR 0.42 (95% CI 0.27-0.66). No clear OS benefit yet. 📌 All prescribed prostate/bed AND pelvic nodal RT, w/ 96 wk ADT. 📌 N+ = CT/MRI >10 mm short axis or path confirmation (PSMA PET alone insufficient if ≤10 mm). Side note: RT dose/fx and PSMA staging use aren't reported in the abstract. #radonc #ESMO26 #PCSM

🚨 ESMO 2026 presidential | DeLLphi-305: Phase III (n=563): Tarlatamab + Durvalumab vs Durvalumab as 1L maintenance after chemo-IO. 📊 Key results: • Median OS: 21.1 vs 12.7 months (HR 0.42) 🔥 • 12-month OS: 79.4% vs 53.3% • Median PFS: 7.4 vs 1.9 months (HR 0.34) • ORR: 26.4% vs 4.1% ⚠️ Grade ≥3 AEs: 46.8% vs 40.6%; CRS 49.6% (mostly low grade). 💡 58% reduction in risk of death! Could this redefine first-line maintenance in ES-SCLC? Probably yes. Looking forward towards full data set . @OncoAlert @esmo #esmo26 #SCLC #DeLLphi305

ESMO 2026 - presidential LBA | VOLGA Phase III – Perioperative Durvalumab + Enfortumab Vedotin (EV) in cisplatin-ineligible/refusing patients: 📊 EV + Durva vs Control • 2-year EFS: 64% vs 45% (HR 0.51; p<0.0001) • 2-year OS: 78% vs 69% (HR 0.58; p=0.0027) • pCR: 45% vs 10% Adding tremelimumab improved EFS (HR 0.61) but no significant OS benefit yet, with higher grade 3/4 toxicity (42% vs 30%). 🔥can this stop the need of post op EV ? Probably yes . New SOC 🙂👍 Looking forward the full datasets @OncBrothers @OncoAlert @myESMO #ESMO26 #VOLGA #BladderCancer

#ESMO26 | DeLLphi-305 – Phase III | Presidential Symposium-1 In ES-SCLC, tarlatamab + durvalumab maintenance significantly improved outcomes vs durvalumab alone following first-line chemotherapy + durvalumab: OS: 21.1 vs 12.7 months (HR 0.42) PFS: 7.4 vs 1.9 months (HR 0.34) CRS: 49.6%; grade ≥3: 0.4%. An impressive OS benefit! Atezolizumab + lurbinectedin maintenance also demonstrated an OS benefit in IMforte (HR 0.73). Although cross-trial comparisons are inappropriate, the magnitude of the OS benefit with tarlatamab appears numerically much greater.

#ESMO26 | KEYNOTE-B49 In patients with PD-L1 CPS ≥1, HR+/HER2− mBC previously treated with ET, pembro + chemo was compared with chemo - PFS: 6.7 vs 6.0 mo (HR 0.74) - OS: 21.0 vs 22.2 mo (HR 1.04) - CPS ≥10: PFS HR 0.59 I’m curious to see the subgroup analyses presented at ESMO. However, in the ADC era, this modest PFS benefit without an OS advantage has little clinical relevance to me. Evaluating immunotherapy in combination with ADCs or after ADC treatment may be more rational in today's treatment landscape.

#ESMO26 | PREDICT-HER – Phase II Can we biopsy every metastatic lesion in breast cancer? No. But can we indirectly assess whole-body HER2 expression using HER2-PET? Possibly! In 89 patients receiving T-DXd, median PFS was 27.5 vs 13.6 months in HER2-PET-positive vs negative patients (HR 0.11). In HER2-low/zero patients, HER2-PET positivity had a 93.8% positive predictive value for response. An exciting approach to capturing HER2 heterogeneity and refining patient selection for T-DXd.

So happy to see my friend Dr. @NarjustFlorezMD honored by Dr. @Tony_Calles and @tactics_md at an #ESMO26 reception full of close friends. https://t.co/4cVswXcQki